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ABSTRACT OF DISSERTATION

POST-TRANSCRIPTIONAL REGULATION OF AFP AND IgM GENES

Gene expression can be regulated at multiple steps once transcription is initiated.
I have studied two different gene models, the α-Fetoprotein (AFP) and the
immunoglobulin heavy chain (IgM) genes, to better understand post-transcriptional gene
regulation mechanisms. The AFP gene is highly expressed during fetal liver
development and dramatically repressed after birth. There is a mouse strain-specific
difference between adult levels of AFP, with BALB/cJ mice expressing 10 to 20-fold
higher levels compared to other mouse strains. BALB/cJ mice express low levels of
Zhx2 and thus incompletely repress AFP. Despite differences in steady state AFP
mRNA levels in the adult liver between Balb/cJ and wild-type mice, transcription rates
across this gene were similar, indicating a post-transcriptional regulatory mechanism. I
found accumulated unspliced RNA across multiple AFP introns in wild-type mice where
mature AFP mRNA levels are low, suggesting overall AFP splicing is inefficient in the
presence of Zhx2. The IgM gene is alternative processed to produce two mRNA
isoforms through a competition between cleavage/polyadenylation (µspA) and splicing
reactions and the pA/splice RNA expression ratio increases during B cell maturation.
Cotranscriptional cleavage (CoTC) events, driven by specific cis-acting elements, are
required downstream of some poly(A) signals to terminate transcription. In some cases,
a pause site can produce similar effect. I explored whether there is a CoTC-like element
within the IgM gene that may contribute to developmental changes in the mRNA ratio. In
both a B cell and plasma cell line there was a gradual decrease in transcripts
downstream from the µspA signal, suggesting that there is not evidence for a CoTC
element within the IgM gene. To examine the effect a CoTC element would have on the
competition between the splice and µspA reactions, we inserted the CoTC sequence of
the β-globin gene into different locations downstream of the µspA signal. While the βglobin CoTC element caused cotranscriptional cleavage in all locations, it only affected
the µspA/splice ratio when located close to the µspA site. This suggests there is a

position effect of the inserted CoTC element on the competing polyadenylation and
splicing reactions within the IgM transcripts.
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CHAPTER I

INTRODUCTION
Changes in gene expression are critical for proper cellular differentiation during
development and cell survival.
environmental conditions.

It also allows adequate response to different

Gene expression can be modulated at different levels,

including transcriptional regulation, to produce a functional mRNA.

Transcription of

protein-encoding-genes is a highly complex process carried out by the RNA polymerase
II complex (RNAPII) which includes several steps: pre-initiation complex assembly,
transcription initiation, transcription elongation and transcription termination. Each of
these steps are tightly coupled to multiple steps of mRNA maturation (capping, splicing
and cleavage/polyadenylation), and rigorously regulated to modulate gene expression.
To better understanding the impact of RNA processing on gene expression, several
transcriptional steps that are targets for gene regulation will be discussed in this thesis
using two different gene models:

the alpha-fetoprotein (AFP) gene to study the

mechanism of post-natal repression mediated by splicing regulation and the
immunoglobulin M (µ) gene to investigate the effect of co-transcriptional cleavage
(CoTC) on developmental RNA processing and transcription termination.

The

introduction will consist of a general overview of transcription by RNAPII and how it is
coupled to RNA processing followed by specific background information regarding the
two genes used in this study, the AFP and the mouse µ genes.
CO-TRANSCRIPTIONAL RNA PROCESSING
The reactions involved in the maturation of mRNA are now known to often occur
co-transcriptionally as the RNA is extruded from the actively transcribing RNAPII. This
observation has changed the old view of eukaryotic gene expression in which the mRNA
processing reactions were thought to occur post-transcriptionally, one independent of
the other. The new model is more dynamic and integrated, where a cross-talk between
factors involved in each of these reactions ensure accurate processing in a spatialtemporal manner which also allows for complex regulation (Bentley, 2005; Kornblihtt et
al., 2004).
Coupling of transcription with RNA processing is mediated by a unique feature of
the RNAPII, the C-terminal domain (CTD) of its largest subunit, Rbp1.

The CTD

contains multiple heptapeptide repeats (26 in yeast and 52 in mammals) with the
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consensus sequence Y1S2P3T4S5P6S7, which is the target of regulatory phosphorylation
at serines 2, 5 and 7. The phosphorylation state of the CTD (“CTD code”) is a dynamic
process that changes as transcription across the gene proceeds, and the CTD is thought
to act as a landing pad that orchestrates the recruitment of factors involved in
transcription elongation and mRNA processing. CTD phosphorylation at Ser5 occurs at
early stages in transcription and promotes association with capping enzymes and
promoter release.

In contrast, CTD phosphorylation at Ser2 increases as RNAPII

progresses through the body of the gene with a maximum peak at the 3’-end, and it is
correlated with transcription elongation, cleavage and polyadenylation and transcription
termination (Bentley, 2005; Kornblihtt et al., 2004)
During transcription initiation, RNAPII binds to the promoter along with the
general transcription factors (GTFs) to form the Pre-Initiation Complex (PIC) (Figure 1-1,
Step 1).

Soon after, CTD phosphorylation at Ser5 by the GTF TFIIH takes place.

Recruitment of 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole sensitivity-inducing
factor (DSIF) and negative elongation transcription factor (NELF) to the transcription
complex results in arrest of productive elongation (Figure 1-1, step 2). This pausing
allows enough time for recruitment of capping enzymes and assembly of the
transcription elongation complex (TEC). Addition of the 5’-cap, a methylated guanosine
attached through an unusual 5’ to 5’ triphosphate linkage, is stimulated by Ser5 CTD
phosphorylation and it occurs as the RNA emerges from the RNAPII when it is about 25
bases long. The 5’-cap is recognized by the cap binding complex (CBC) that in turn
protects the nascent transcript from degradation by 5’-3’ exonucleases and enhances
mRNA translation. Promoter-proximal pausing is relieved by phosphorylation of the CTD
Ser2 mediated by positive transcription elongation factor b (pTEFb), which causes
dissociation of NELF and thus, allows transcription elongation to resume (Figure 1-1,
step 3) (Bentley, 2002; Bres et al., 2008; Mandal et al., 2004; Proudfoot et al., 2002;
Sims et al., 2004a). Once the RNAPII complex transitions to productive elongation, it is
very stable and able to transcribe up to hundreds of kilobases without dissociating from
the DNA template (Nechaev and Adelman, 2011). Phosphorylation of CTD at Ser2 also
serves as platform for binding of factors involved in regulation of transcription elongation,
RNA processing and termination as described latter.
Transcriptional pausing at the promoter-proximal region induced in the early
transcriptional elongation phase, may serve as an important control for gene regulation
by at least three different ways (Chiba et al., 2010): First, it may act as rate-limiting step
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to reduce transcriptional level. Second, it contributes to the maintenance of a “poised”
state where specific-gene activation and transcription initiation processes have been
completed, allowing a rapid response to extracellular signals. It also may favor an open
chromatin structure by preventing nucleosome formation and finally, it allows functional
coupling between transcription and RNA processing ensuring that RNA capping has
been completed before engaging in a productive elongation (Chiba et al., 2010; Nechaev
and Adelman, 2011).
SPLICING REGULATION
Typical mammalian genes are comprised of multiple short exons (<300 bp) which
are interrupted by long intervening sequences (introns). Introns must be removed from
the primary transcript (pre-mRNA) to generate mRNA by a process known as splicing.
About 90% of human genes undergo alternative splicing to give rise more than one
mRNA isoform. Therefore, alternative splicing is an important mechanism to expand the
proteomic diversity from a limited number of genes encoded by the genome. Indeed,
inclusion/exclusion of alternative exons from a primary transcript may result in mRNAs
that encode for protein products with different function, subcellular localization or
catalytic activity, which are important for tissue specific and developmental processes
(Hu and Fu, 2007; Karni et al., 2007; Luco et al., 2011). Moreover, it may introduce
alternative exons or intron retention that results in production of truncated proteins or in
mRNA that are target for degradation by the nonsense-mediated decay (NMD) pathway
(Tazi et al., 2009).
The importance of alternative splicing regulation has been increased because
mis-regulation of mRNA splicing may be involved in human disease, including cancer.
Many genes involved in apoptosis are alternative spliced and the different isoforms can
generate proteins with opposite function. For example, alternative usage of a 5´splice
site coded within exon 2 of the Bcl-x gene can lead to the synthesis of either the proapoptotic isoform Bcl-xS or the anti-apoptotic isoform Bcl-xL (Mercatante et al., 2001).
Additionally, the function of several tumor suppressor genes (Brca1 and Mdm2) and
oncogenes (Kras and Wnt), are also regulated by alternative splicing. Hence, generation
of splice variants from these genes that encode an inactive tumor suppressor or an
active oncogene play a role in cancer (Mercatante et al., 2001; Venables, 2004). Others
genes regulated by alternative splicing include those involved in angiogenesis (VEGF)
and cell adhesion (CD44) whose splicing pattern changes during tumorigenesis (Zerbe
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et al., 2004). Another example is the spinal muscular atrophy (SMA) disorder caused by
the absence of or mutation in the Survival Motor Neuron 1 (SMN1) gene,

which

encodes for an essential protein involved in assembly of the spliceosome (Singh et al.,
2004; Sumner, 2006). The SMN2 gene, which differs by a nucleotide within exon 7, fails
to compensate loss of SMN1 gene, because the nucleotide substitution induces exon 7
skipping and production of a truncated and unstable protein (Singh et al., 2004).
Increased SMN expression levels could be achieved either by modulating splicing of the
SMN2 pre-mRNA, induce stabilization of the SMN protein or SMN1 gene replacement
(Sumner, 2006).
Joining of exons is mediated by the spliceosome which is composed of five
uridine-rich small nuclear ribonucleoprotein particles (snRNPs) called U1, U2, U4, U5
and U6, and multiple non-snRNPs splicing factors. Splicing involves the recognition of
consensus sequences near the intron-exon boundaries and conserved elements in the
introns (Figure 1-2A). The early steps of the spliceosome assembly involve recognition
of the consensus elements at both ends of the intron to form the early (E) complex: U1
snRNP binds to the 5´splice site, the branchpoint-binding protein (BBP) binds to the
branchpoint site, while the heterodimeric U2 snRNP auxiliary factor (U2AF) recognizes
the polypyrimidine tract and the 3´ AG (Figure 1-2B). Next, U2 snRNP is recruited to the
branch site aided by the U2AF which results in the displacement of BBP to form the A
complex.

The tri-snRNP particle, comprised of U4/U6/U5, then joins the complex,

bringing together the two splice sites that lead to the B complex. Once the assembly of
the spliceosome occurs, there is a dynamic rearrangement of interactions that promotes
release of U1 and U4 snRNPs. This results in the formation of the catalytically active
spliceosome known as C complex which carries out the two trans-esterification reactions
leading to intron excision (Cartegni et al., 2002; Dou et al., 2006; Sanford et al., 2005;
Smith and Valcarcel, 2000; Watson, 2004). Although these conserved sequences are
required for splicing, they are not sufficient to determine the correct exonic boundaries.
Regulatory elements such as splicing enhancers and silencers located within either
exons or introns act in both constitutive and regulated splicing. These elements called
exonic or intronic splicing enhancers (ESE/ISE) and exonic or intronic splicing silencers
(ESS/ISS) consist of short highly degenerate sequences that are generally bound by
positive or negative trans-acting splicing factors often serine/arginine-rich (SR) proteins
and heterogeneous nuclear ribonucleoproteins (hnRNP), respectively. Binding of these
regulators to their corresponding cis-acting elements favor or inhibit recruitment of early
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spliceosome components. This plays an important role in the decision of splice site
selection that ultimately determines whether an exon will be included or excluded in the
mRNA (Baralle and Baralle, 2005; Pagani and Baralle, 2004). Indeed, different tissues
show not only differences in relative concentration but also a unique pattern of SR
proteins and hnRNPs. These differences can affect splice choice in multiple RNAs and
contribute to cell-specific gene expression (Smith and Valcarcel, 2000; Zahler et al.,
1993).
Alternative splicing is not only affected by the relative abundance of different
splicing factors at the time a gene is expressed.

Extensive experimental evidence

indicates that the elongation rate, promoter structure, transcription regulators, chromatin
structure and RNA secondary structure also can affect alternative splicing.
A slowed transcriptional elongation rate or increased pausing of the RNAPII led
to enhanced inclusion of exons with weak splice sites, presumably because it gives
more time for the recruitment of splicing factors before the downstream competing splice
site was transcribed (Kornblihtt, 2006; Luco et al., 2011). This was neatly demonstrated
by utilizing reporter minigenes containing the exon 33 (E33 or EDI) of the Fibronectin
(FN) gene and a wild-type or slow mutant of RNAPII. It was observed that the slow
mutant RNAPII stimulates inclusion of the E33 by about 3-fold compared to wild-type
RNAPII (de la Mata et al., 2003; Kornblihtt et al., 2004). Similarly, pause sites can
regulate alternative splicing by temporarily arresting or slowing RNAPII. Insertion of the
MAZ pause element in the tropomyosin gene, between the splice junction and its
regulatory element, enhanced inclusion of tropomyosin exon 3 (Luco et al., 2011;
Roberts et al., 1998)
How promoter structure influences alternative splicing was first discovered
through studies with reporter minigenes containing the alternative exon 33 (E33) of the
FN gene, driven by different RNAPII promoters. It was observed that inclusion of the
E33 exon was about 10 times higher when transcription was driven by the FN or the
CMV promoters than when it was driven by the weaker α-globin promoter (Cramer et al.,
1999; Cramer et al., 1997; Kornblihtt, 2005, 2006).

The effect of the promoter on

alternative splicing can be mediated by differences in promoter occupancy by
transcription factors which then, may impact transcription elongation rates or splicing
factor recruitment, directly or indirectly. For example, the thermogenic coactivator PGC1, is recruited at promoters with DR-1 elements bound by PPARγ. PGC-1 in turn recruits
SRp40, resulting in EDII exon skipping (Kornblihtt, 2005).
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Studies with the FN reporter minigene also revealed that chromatin structure can
impact alternative splicing. It was observed that increased histone acetylation, induced
by the histone deacetylation inhibitor trichostatin A, enhanced skipping of the E33 exon
(Nogues et al., 2002). Moreover, genome-wide analysis has shown that nucleosomes
are strikingly enriched on exons as compared to introns, suggesting they may participate
in the exon definition process (Schwartz et al., 2009). The average exon size is 140-150
nt, compared to the nucleosome occupancy of 147 nt of DNA. In addition, nucleosomes
are even more prominent in exons with weaker splice sites, suggesting that they may
regulate alternative splicing. Furthermore, some histone modifications are specifically
enriched in exonic nucleosomes compared to their flanking intronic regions; these
modifications possibly mark the nucleosomes for binding to RNA-processing factors
(Luco et al., 2011; Perales and Bentley, 2009). In addition, histone modifications can
function as docking sites for chromatin binding factors. A nice example of the correlation
between histone modifications and alternative splicing was recently reported by SaintAndré et al. (2011). They demonstrated that H3K9 trimethylation is specifically enriched
throughout the alternative exons of the CD44 gene. This histone mark functioned as
binding sites for phosphorylated HP1γ, which mediated the inclusion of CD44 alternative
exons. They noticed that HP1γ induces accumulation of RNAPII on the alternative exon
region and therefore suggested a decrease in the transcription elongation rate.

In

addition, HP1γ also stabilizes association between the nascent RNA with the chromatin
which may also enhance the inclusion of the CD44 alternative exons (Saint-Andre et al.,
2011).

CO-TRANSCRIPTIONAL SPLICING AND TRANSCRIPTION COUPLING
Initial evidence that splicing is co-transcriptional came from analyses of nascent
transcripts of Drosophila embryo by electron microscopy.

These data visualized

ribonucleoprotein assembly and intron looping on nascent transcripts occurs still
attached to RNAPII (Beyer and Osheim, 1988). A recent analysis of the c-Src and the
FN pre-mRNAs from chromatin-associated and nucleoplasmic RNA fractions revealed
that most introns are removed before the transcript is released from the chromatin
(Pandya-Jones and Black, 2009). However, introns flanking constitutive exons were
removed in a 5’-3’ fashion, while introns neighboring alternative exons showed
differences in excision efficiency, indicating they were not removed in a strict 5’-3’
direction, likely allowing for regulation.
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This and numerous other studies establish that the splicing machinery is
recruited and introns are committed to splice co-transcriptionally, indicating that the
decision of whether an exon will be included or skipped is generally determined before
the nascent transcript is released. However, this does not rule out that splicing of some
introns will occur post-transcriptionally. Additional evidence that splicing is coupled to
transcription is the interaction between splicing factors including SR proteins and U1
snRNP with the RNAPII (Luco et al., 2011).
ALTERNATIVE SPLICING AND THE NONSENSE-MEDIATED DECAY PATHWAY
Nonsense-mediated mRNA decay (NMD) is a conserved surveillance pathway
present in eukaryotes for degradation of transcripts containing premature termination
codons (PTC). This prevents translation of mRNA that would produce deleterious
truncated proteins. Indeed, about 30 % of inherited genetic disorders would be
generated as result of nonsense mutations or frameshifts that introduce nonsense
codons and degradation of those transcripts by NMD, has been shown to ameliorate the
disease phenotype. The intriguing conservation of NMD among the eukaryotes has
suggested other functions for NMD pathway. Bioinformatic analyses point out that about
10 % of naturally occurring transcripts would produce alternative splice variants
containing a PTC. Thi suggests a mechanism that couples alternative splicing with NMD
to achieve a suitable regulation of gene expression by modulating the stability of target
transcripts in a given developmental or physiological condition. By means of this
mechanism, the NMD pathway plays an important role in regulating diverse biological
processes such as cell proliferation, cell cycle, metabolism, transcription and telomere
maintenance (Behm-Ansmant and Izaurralde, 2006; Boelz et al., 2006; Frischmeyer and
Dietz, 1999; Mendell et al., 2004).
Activation of the NMD pathway relies on protein complexes deposited 20-24
nucleotides upstream of exon-exon boundaries. These multiprotein complexes, referred
to as exon junction complexes (EJCs), serves as platform for assembly of the NMD
effectors (Upf1, Upf2 and Upf3) that lead to mRNA degradation when premature
termination codons are recognized (Behm-Ansmant and Izaurralde, 2006). A simple
model of NMD pathway activation is depicted in Figure 1-3. In this model, Upf3 is
recruited to the mRNA during splicing by interactions with the EJC, while Upf2 may join
the complex after mRNA export. During the first round of translation, Upf2, Upf3 and
other components of the EJC are removed as ribosomes trasverse the mRNA, while
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stop codons are recognized by the eukaryotic release factors (eRF1 and eRF3).
Detection of a PTC, which is defined as a stop codon located more than 50 nucleotides
upstream of an exon-exon junction, will avoid complete removal of downstream Upf
proteins and therefore, recruitment of Upf1. This triggers phosphorylation of Upf1 and
rapid degradation of mRNA by decapping enzymes and 5’-3’ exonucleases (BehmAnsmant and Izaurralde, 2006; Chang et al., 2007).
CLEAVAGE/POLYADENYLATION AND TRANSCRIPTION TERMINATION by RNAPII
Transcription termination is described as the process by which RNA polymerase
ceases transcription and releases the nascent RNA and DNA template (Figure 1-1, step
4).

RNAPII release generally occurs downstream of the poly(A) site, which allows

polymerase recycling and prevents interference at downstream promoters. Although
transcription termination by the RNAPII is not completely understood, it is known that it
requires a functional poly(A) site and is coupled to 3’-end mRNA processing (Dye and
Proudfoot, 2001; Gromak et al., 2006). Poly(A) signals of protein-coding genes contain
a conserved hexanucleotide sequence, AAUAAA and a G/U-rich or U-rich element
located 10-50 nucleotides downstream. The 3’-end processing of most mRNAs is a twostep reaction involving the cleavage at a CA between the AAUAAA and the G/U-rich
elements and the addition of about 200 adenosines at the 3’-end of the mRNA (Figure 14A).

The

cleavage and

polyadenylation

machinery

includes

cleavage

and

polyadenylation specificity factor (CPSF) that binds to the AAUAAA sequence. It is
stabilized by binding of cleavage stimulatory factor (CstF) at the G/U-rich element,
followed by the cleavage factors I and II (CFI/CFII) (Figure 1-B). Rapid addition of the
poly(A) tail at the exposed 3’-OH is carried out by the poly(A) polymerase (PAP) and
thus, the mRNA is stabilized. The downstream cleavage product, having an uncapped
5’-end is, instead, highly unstable and rapidly degraded (Bentley, 2005; Gromak et al.,
2006; Perales and Bentley, 2009; Rosonina et al., 2006).
Recruitment of 3’-end processing factors start at the promoter of proteinencoding genes. CPSF is recruited to the pre-initiation complex by the general
transcription factor TFIID. Once transcription initiates, CPSF dissociates from TFIID and
associates with the transcription elongation complex (TEC), presumably by binding to
the RNAPII body (Dantonel et al., 1997).

The CstF complex, composed of three

subunits (CstF50, CstF64 and CstF77), assembles during transcription. This is based
on the finding that Cst64 localizes close to the transcription start site while CstF77 is
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detected downstream of the poly(A) signal in MYC, GAPDH and p21 genes (GloverCutter et al., 2008). CPSF binds to CstF and RNAPII in a mutually exclusive manner.
This suggests that the formation of a functional CPSF and CstF complex may be
modulated by transference of CPSF from the RNAPII body to CstF at the CTD, and
subsequently to the nascent RNA after the poly(A) signal is synthesized (Glover-Cutter
et al., 2008; Nag et al., 2007; Perales and Bentley, 2009).
RNAPII pausing generally occurs within 0.5 and 2 Kb downstream of the poly(A)
site. Pausing at the 3’-end of genes correlates with maximal CTD Ser2 phosphorylation
and high level of 3’-processing factors recruitment. It is thought that pausing at the 3’end coordinates poly(A) site processing and transcription termination by an uncertain
mechanism.

Indeed, many proteins involved in cleavage/polyadenylation are also

required for transcriptional termination, such as Pcf11 and Rat1 (Xrn2 in mammals).
The Pcf11 subunit of CFII is required for both processes. Beside its role in pre-mRNA
cleavage, Pcf11 has been suggested to act as a terminator factor by directly binding to
Ser2 CTD and destabilizing the TEC (Zhang and Gilmour, 2006). The yeast 5’-3’ RNA
exonucleases Rat1 is recruited to the CTD during transcription and is implicated to
promote recruitment of cleavage/polyadenylation factors essential in termination (Luo et
al., 2006). It also has been suggested that upon 3’-end RNA cleavage, Rat1/Xrn2 is
responsible for 5’-3’ degradation of the nascent transcript and possibly, aids in the
RNAPII release (Bentley, 2005; Luo et al., 2006; Rosonina et al., 2006; West et al.,
2004).
Some poly(A) signals have the intrinsic ability to pause RNAPII and direct
transcription termination in model constructs (Orozco et al., 2002).

In these cases,

termination occurs as a gradual decrease in RNAPII loading over hundreds to thousands
bases downstream of the poly(A) signal, depending on the poly(A) strength (Orozco et
al., 2002). However, additional downstream elements have been reported to increase
termination efficiency in several genes. These sequences may be critical for closely
spaced genes to avoid transcription into promoters of downstream genes. Such is the
case of the human complement C2 gene, spaced just 421 bp from the Factor B gene. It
was demonstrated that transcription termination in the C2 gene occurs just downstream
of the poly(A) site, mediated by a 160 bp G-rich sequence that may bind the zinc finger
protein MAZ.

MAZ binding induced pausing of the RNAPII and additionally, DNA

bending that may favor disassembling of the TEC (Ashfield et al., 1991; Ashfield et al.,
1994).
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Pause sites are also reported to aid in transcription termination, which is the case
in the human Gγ-globin (Plant et al., 2005) and α2-globin genes (Enriquez-Harris et al.,
1991). The human Gγ-globin termination element consist of multiple weak pause sites
and a strong poly(A) signal. In contrast, the pause site in the α2-globin gene consists of
a 92 bp long sequence combined with a weaker poly(A) signal. The α2-globin pause
site contains a nearly perfect (CAAAA)6 repeat proposed to either form a specific
structure to the DNA template or binding site for a protein binding to the nascent RNA
(Enriquez-Harris et al., 1991).
More recently, another elment required for efficient termination was identified in
the 3’ flanking region of the human β-globin gene. This element is positioned between
900 and 1600 bp downstream of the poly(A) site and contains the unique ability to
undergo cotranscriptional cleavage (CoTC) by a poorly understood mechanism (Dye et
al., 2006; Dye and Proudfoot, 2001; Teixeira et al., 2004). This element was uncovered
by performing a run-on assay with nascent transcripts selected using an antisense
biotinylated RNA probe targeting the poly(A) region (Dye and Proudfoot, 2001).
Transcripts containing the sequences downstream of the CoTC region were not
contiguous with the selected RNA, suggesting that they were cleaved. This was further
confirmed by reverse transcription followed by PCR (RT-PCR) using primers spanning
the region downstream of the poly(A) site. Deletion of the CoTC sequence eliminated
transcription termination but did not affect 3’-end processing. The absence of 3’-end
processing, by mutating the poly(A) signal, also abolished termination but did not affect
cleavage within the CoTC region. Therefore, both 3’ end processing and CoTC were
required for transcription termination (Dye and Proudfoot, 2001). Gromak et al. (2006)
also demonstrated that the β-globin CoTC element can be replaced by four tandem MAZ
pause elements to support transcription termination in a poly(A)-dependent manner in
this transcripiton unit.
Similar to the β-globin CoTC element, sequences undergoing cleavage
downstream of a poly(A) site have been identified in the ε-globin gene (Dye and
Proudfoot, 2001) and more recently in the mouse serum albumin gene (MSA) (West et
al., 2006).

However, they differ from the β-globin CoTC element in various

characteristics. The ε-globin termination elements are more diffuse and involve long
tracts of the 3’ flaking region, which corresponds to differences in transcription
termination profiles; transcription termination in the β-globin gene occurs abruptly within
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the 3’ flanking region while transcription termination in the ε-globin gene occurs gradually
over about 1.65 kb downstream of the poly(A) site (Dye and Proudfoot, 2001). Unlike
the MSA CoTC element, the human β-globin CoTC is A/U-rich (West et al., 2006).
As decribed above, there is a considerable sequence heterogeneity among the
termination elements identified, making their existence difficult to predict without a
functional assay.

But their effect on transcription temination, in all the cases, is

dependent on a poly(A) signal.
The current model of transcription termination postulates that there is a
cooperative association of Rat1 and cleavage/polyadenylation factors, such as Pcf11,
with the Ser2 CTD. When the poly(A) signal is transcribed and recognized by these
factors, this may induce allosteric changes in the RNAPII, making it prone to termination.
This may be enhanced by additional sequences that act to pause or slow RNAPII
transcriptional elongation. Cleavage of nascent RNA at the poly(A) site or at a CoTC
element leads to two RNA products; the mRNA is rapidly polyadenylated, while the 3’cleavage product which remains attached to the RNAPII is targeted for degradation by
5’-3’ exonucleases Rat1/Xrn2.

Rat1/Xrn2-induced degradation may aid to release

RNAPII (Gromak et al., 2006; Luo et al., 2006).
As has been discussed, regulation of gene expression is a very complex process
that involves not only control of transcription initiation, transcription elongation and
transcription termination, but also it can be modulated at different RNA processing steps.
For instance, regulation of alternative RNA splicing may lead expression of proteins with
different functions or subcellular localization, or even mRNAs that differ in stability.
Better understanding of the mechanism by which genes are tightly regulated may
generate therapeutic tools that could be used for amelioration of human diseases such
as spinal muscular atrophy and cancer. Here, I will discuss two different gene models,
the AFP and the IgM (µ) genes, that we study to gain insight into mechanisms coupling
transcription with RNA processing. First, I will give some background information on
what is known about the AFP and µ gene regulation.

ALFHA-FETOPROTEIN FUNCTION AND DEVELOPMENTAL GENE EXPRESSION
The α-fetoprotein (AFP) gene consists of 15 exons that encode a glycoprotein of
about 70 KDa with a carbohydrate (glycan) moiety (Mizejewski, 2004; Peterson et al.,
2011). The AFP gene is member of the serum albumin gene family which consists of
five members, Albumin (Alb), vitamin D-binding protein (DBP), α-fetoprotein (AFP), α-

11

albumin or afamin (α-Alb or Afm) and AFP-related gene (Arg) protein, that all evolved
from a common ancestor gene by a series of duplication events (Mizejewski, 2011;
Peterson et al., 2011). Although AFP function remains poorly understood, it has been
reported to be involved in the regulation of growth and differentiation during development
and it binds and transports many ligands including bilirubin, fatty acids, hormones,
retinoids, steroids, heavy metals, dyes, dioxins and organic drugs (Mizejewski, 2004).
AFP is expressed at high levels and secreted by the yolk sac, liver and, to a
lesser extent, the gastrointestinal tract during fetal development.
4

After birth AFP

5

expression gradually decreases about 10 -10 -fold and remains at a low basal level
throughout adult life (Belayew and Tilghman, 1982; Olsson et al., 1977).

However,

increased serum AFP is associated with liver and germ cell tumors and therefore, is
used as biomarker for detection of these abnormalities. In pregnant women, AFP levels
are also measured using maternal blood or amniotic fluid to screen for neural tube
defects and Down syndrome (Spear et al., 2006).
Much of the work to understand AFP expression and the dramatic decrease in
AFP expression after birth has been done in mice (Belayew and Tilghman, 1982; Olsson
et al., 1977). Early studies to understand the mechanisms of postnatal AFP silencing
were performed by measuring the serum AFP levels in adult mice of different inbred
strains. BALB/cJ mice were found to express up to 20-fold higher serum AFP levels
compared to other mouse strains. The post-natal persistence of AFP expression is a
recessive trait controlled by a gene called raf (regulation of AFP) and later renamed Afr1
(Alpha-fetoprotein regulator 1) (Olsson et al., 1977). Subsequently, it was shown that
the higher levels of AFP in BALB/cJ correlated with higher steady-state liver AFP mRNA
levels. AFP expression also is reactivated in adult liver during liver regeneration but this
induction is controlled by another gene named rif (regulation of induction of AFP) or Afr2
(Belayew and Tilghman, 1982).
Linkage analysis initially mapped the Afr1 gene to mouse chromosome 15
(Blankenhorn et al., 1988). Then, performing a positional cloning using a high-resolution
mapping, Afr1 was identified as the Zinc-fingers and homeoboxes 2 (Zhx2) gene
(Perincheri et al., 2005). This analysis revealed that the BALB/cJ Zhx2 allele contains
an ETnIIα endogenous retroviral element insertion within the intron 1. While normal
transcription initiation of the Zhx2 gene in BALB/cJ mice occurs, most pre-mRNAs splice
to the retroviral element and a very low fraction of the mRNA is properly spliced to
encode full length Zhx2 mRNA. This hypomorphic mutation dramatically reduces Zhx2
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expression in BALB/cJ adult mice compared to other mouse strains expressing the wildtype Zhx2 allele (Perincheri et al., 2008). Lower Zhx2 expression in adult BALB/cJ mice
correlates with increased accumulation of liver AFP and H19 mRNA levels, indicating the
role for Zhx2 in repressing expression of both genes in perinatal liver.
expression

of

a

Zhx2

transgene

driven

by

a

liver-specific

In fact,

transthyretin

enhancer/promoter in BALB/cJ mice led to complete repression of AFP and H19 in adult
liver, confirming that Zhx2 is responsible for the Afr1 phenotype (Perincheri et al., 2005).
Moreover, levels of Zhx2 are observed to increase after birth as AFP levels decrease,
consistent with the role of Zhx2 in AFP repression.
The H19 gene was isolated as another target of Zhx2 through a screen for
murine fetal liver cDNA clones that had decreased expression after birth (Pachnis et al.,
1984). The H19 gene product is a long non-coding RNA, 2.4 kb in length, which has
been extensively studied as model of genomic imprinting (Brannan et al., 1990; Pachnis
et al., 1988). More recently, the cell-surface proteoglycan 3 (Gpc3), which belong to a
family of proteins associated with cell growth, development and growth factor responses,
was also identified to be regulated by Zhx2 (Morford et al., 2007). Deregulation of Gpc3
expression has been associated with Simpson-Golabi-Behmel syndrome characterized
by general overgrowth as well with different types of tumors. Zhx2 may also control
many other genes based on recent work in which a quantitative trait locus (QTL) on
chromosome 15, called Hyperlipidemia 2 (Hyplip2), involved in regulation of cholesterol
and triglyceride levels, was identified to be Zhx2. BALB/cJ mice, which express very low
levels of Zhx2, showed reduced serum cholesterol and triglyceride levels compared to
other mouse strains. Additionally, complementation with a Zhx2 transgene resulted in
increased-serum cholesterol and triglyceride levels as compared to other mouse strains,
indicating Zhx2 is responsible for this trait.

Comparison of global gene expression

analysis from livers of BALB/cJ and Zhx2-expressing mice indicated that about a
thousand genes were differentially expressed, some of which are known to be involved
in liver function and plasma lipid metabolism. From this study, Lipoprotein lipase (Lpl)
was reported as a new target of Zhx2 which showed a similar pattern of developmental
expression like AFP, H19 and Gpc3.

However, the Ear11 gene, a member of the

eosinophil-associated ribonuclease family, showed the opposite expression pattern,
suggesting that Zhx2 function may act in a context-dependent manner (Gargalovic et al.,
2010).

Interestingly, known targets of Zhx2 such as AFP, H19, Gpc3 and Lpl are

generally elevated in liver tumors (Gargalovic et al., 2010; Spear et al., 2006).
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ZINC FINGER AND HOMEOBOXES (ZHX) FAMILY
The Zinc fingers and homeoboxes (ZHX) family consists of three members,
ZHX1, ZHX2 and ZHX3. Human ZHX1 was identified as a NF-YA interacting protein by
screening a human liver cDNA library using a yeast two-hybrid system (Yamada et al.,
1999).

ZHX1 was independently isolated by immunoscreening of a bone marrow

stromal cell cDNA library (Barthelemy et al., 1996; Yamada et al., 1999). Human ZHX2
and ZHX3 were identified later as ZHX1-interacting proteins by screening rat liver and
ovarian granulosa cell cDNA libraries using ZHX1-fused to the GAL4-DBD as bait in a
yeast two-hybrid system.

ZHX proteins are reported to form homodimers and

heterodimers with each other as well with NF-YA (Kawata et al., 2003a; Kawata et al.,
2003b; Yamada et al., 2003).
All ZHX proteins contain two C2H2-type zinc finger domains and 4 (ZHX2 and
ZHX3) to 5 (ZHX1) homeodomains. They also share similar gene structure, consisting
of 4 exons where the proteins are encoded by an unusual long exon (exon 3) with the
exception of the ZHX3, in which the last 8 nt are encoded by the last exon. ZHX1 is
linked to ZHX2 in chromosome 8 (Chromosome 15 in mouse) while ZHX3 is located on
chromosome 20 (Chromosome 2 in mouse). Based on the sequence similarities, gene
structure and phylogenetic analysis of mouse ZHX proteins, it was suggested that ZHX
genes were originated from a common ancestral gene by two different duplication events
(Kawata et al., 2003a; Spear et al., 2006).
Analysis of tissue distribution of human ZHX mRNAs by Northern blot indicated
that they are ubiquitously expressed, although transcript levels varied among the tissues
examined (Kawata et al., 2003b; Yamada et al., 2003; Yamada et al., 1999). ZHX1
mRNA showed two major transcripts of 4.5 and 5 kb, Zhx2 is expressed as a single
transcript of 4.4 kb, while ZHX3 is expressed as multiple mRNAs of 9.4, 7.3, 5.0 and 4.6
kb. Similar analysis of Zhx2 mRNA from mouse tissues indicated that a single 4.4 kb
Zhx2 transcript is also ubiquitously expressed, although levels are lower in liver and in
testis than the other tissues assayed (Perincheri, 2005). ZHX genes are also expressed
in all vertebrates analyzed including human, rodents, dogs and zebrafish but
homologues are not found in non-vertebrates such as Drosophila, Caenorhabditis
elegans and yeast, suggesting that ZHX proteins are restricted to the vertebrate lineage
(Spear et al., 2006).
ZHX2 has been called a transcriptional repressor based on a cell culture system
utilizing a luciferase reporter gene driven by 5 copies of the GAL4-DNA binding domain.
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Co-transfecting HEK293 cells with a plasmid expressing ZHX2 fused to the GAL4 DNAbinding domain reduced luciferase activity by a maximum of 25% in a dose-dependent
manner. Additionally, ZHX2 was shown to interact with NF-YA in vitro and in vivo,
suggesting that ZHX2 may regulate genes that are regulated by the NF-Y transcription
factor. In this regard, a luciferase reporter gene driven by the promoter region of the
cdc25C gene responsive to NF-Y was used to co-transfect Drosophila SL2 cells. Cotransfection of NF-Y expression plasmids activated luciferase expression in these cells,
and this expression was reduced about 30% by co-transfection with a ZHX2-expressing
plasmid in a dose-dependent manner (Kawata et al., 2003b).

Similar assays were

performed with other promoters responsive to NF-Y in order to determine the repressor
activity of all three ZHX proteins. The M2-type pyruvate kinase (MPK) promoter was
modestly repressed by ZHX1 and ZHX3, the Hexokinase II (HKII) promoter was
repressed by all ZHX proteins, and the cdc25C promoter was repressed by ZHX2 and
ZHX3. These results indicated that members of the ZHX family negatively regulate
expression of genes stimulated by NF-Y, although with differences in activity and
specificity (Yamada et al., 2009).
The list of physiological functions of Zhx proteins has increased over the recent
years, and all indicate they have important roles in cell differentiation and in disease.
Briefly, ZHX proteins are reported to modulate podocyte gene expression during
development of nephritic syndrome, where down-regulation of ZHX3 preceded
proteinuria, a frequent complication in primary podocyte disorders (Liu et al., 2006). In
another study, it was shown that ZHX2 is specifically expressed in neural progenitor
cells during cortical neurogenesis.

Its interaction with the cytoplasmic fragment of

Ephrin-B in the nucleus regulates transcription and subsequent inhibition of cell
differentiation required for neural progenitor cell maintenance (Wu et al., 2009). ZHX2
also was down-regulated in patients with hereditary persistence of fetal hemoglobin
(HPFH) and δβ-thalasemia. The genomic region where ZHX2 lies on chromosome 8 is
associated with a quantitative trait locus that influences the switch from fetal to adult
hemoglobin, and found to be responsible for HPFH (De Andrade et al., 2010). Finally, a
gene expression profile performed to determine potential genes involved in clinical
behavior of multiple myeloma (MM) indicated that high levels of ZHX2 expression
correlated with better response and survival after high-dose therapy (Armellini et al.,
2008). All the examples listed above suggest that ZHX proteins are involved in the
control of genes that are involved early in development.
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Other studies have suggested that ZHX2 is deregulated during liver cancer
progression. Lv et al. reported that silencing of ZHX2 by promoter hypermethylation was
observed in about half of the Hepatocellular Carcinoma (HCC) samples analyzed
compared to control samples (no tumor). ZHX2 mRNA levels in these HCC samples
were inversely correlated with serum levels of AFP (Lv et al., 2006).

However, in

another report, ZHX2 protein expression was analyzed by immunohistochemistry of
tissue microarrays from liver tissues obtained from cholangitis, cirrhosis, adjacent nontumor tissues, primary HCC tissues and matched metastatic lesions, and found that
ZHX2 expression was detected only in HCC tissues.

Higher expression of ZHX2

correlated with HCC clinical stage III and IV compared to stage I and II, and in metastatic
lesions compared to primary HCC lesions (Hu et al., 2007). Because these studies
come to opposite conclusions regarding a potential role for ZHX2 in HCC progression,
further studies are warranted in this area.

AFP REGULATORY ELEMENTS
Regulatory elements that drive mouse AFP expression are contained within a 7.6
kb DNA region upstream of the AFP transcription start site and include the promoter, a
repressor and three enhancer elements. The AFP promoter consists of 250 bp directly
adjacent to exon 1 and its activity is restricted to the liver. It contains multiple binding
sites for liver-enriched and ubiquitous transcription factors including the Hepatocyte
Nuclear Factor 1 (HNF1), Nuclear Factor 1 (NF1), CAAT/Enhancer binding protein
(C/EBP), Fetoprotein transcription factor (FTF) and Nkx2.8.

An overlapping site for

HNF1 and NF1 binding located at -120 from the AFP transcription start site has been
reported to contribute to the promoter activity (Feuerman et al., 1989; Spear, 1999). In
fact, it has been reported that a single nucleotide substitution in human at two different
HNF1 binding sites within the AFP promoter (-60 and -120) are associated with
hereditary persistence of AFP (Alj et al., 2004; Blesa et al., 2003). More recently it was
reported that the Zinc finger and BTB domain containing 20 (ZBTB20) is involved in
transcriptional repression of AFP in perinatal liver by binding to the region between -108
and -53 of the mouse the AFP promoter (Xie et al., 2008).
A repressor region located between the -250 and -838 bp region was reported to
be required for postnatal AFP repression, since an AFP transgene lacking this region
continued to be expressed in adult liver (Vacher and Tilghman, 1990).

Additional

binding sites for Foxa and p53 family members, p53 and p73, are located around the -
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850 bp region. Interference of Foxa binding at this site by p53 is suggested to contribute
to post-natal AFP repression (Peterson et al., 2011; Xie et al., 2008). However, in other
studies, the 250 bp promoter without this repressor region was sufficient to repress a
heterologous reporter gene in transgenic mice (Peyton et al., 2000a)
The three enhancers, referred to as E1, E2 and E3, are positioned at about -2.5,
-5.0 and -6.5 kb, respectively, and are each about 200-300 bp (Godbout and Tilghman,
1988). E1 and E2 enhancers showed higher similarity suggesting they arose from a
duplication event; moreover, E1 is present in rodent but it is absent in other species
analyzed (Long et al., 2004).

Studies in transgenic mice indicated that the three

enhancers are active in both fetal and adult mouse livers (Ramesh et al., 1995). In the
adult liver, E1 and E2 are active in all hepatocytes while E3 is active only in hepatocytes
around the central vein due to continuous repression of this enhancer in non-pericentral
hepatocytes (Peyton et al., 2000b).

REGULATION OF AFP POST-NATAL REPRESSION BY ZHX2
The AFP cis-acting elements required for Zhx2 responsiveness have been
studied using mouse models.

Although the cis-acting elements required for

transcriptional activation of AFP expression, such as the enhancer and promoter
regions, have been well characterized in cultured cells, the developmental silencing
observed in vivo has not been reproduced in these in vitro systems. The BALB/cJ
mouse strain, containing the Zhx2 mutation that results in incomplete post-natal AFP
repression has been an important tool for studying this process. Because the mouse
AFP gene consists of 15 exons and is about 22 kb, the use of AFP minigenes allows
ease of manipulation for deletion and mutation of sequences that may impact AFP
regulation. Minigenes also can be distinguished from the endogenous AFP gene for
measuring gene expression.

To study Zhx2-mediated regulation, transgenic mice

expressing AFP minigenes were generated in a mouse strain expressing Zhx2 and
backcrossed twice to BALB/cJ. F2 offspring were genotyped to screen for transgenic
mice heterozygous or homozygous for the recessive Zhx2 mutant allele. Initial studies in
cultured cells and transgenic mice utilized an AFP minigene that consisted of the two
first and three last exons linked to the 7.6 kb 5’-flanking region of AFP gene. This
minigene was developmentally regulated and expressed in the same tissue-restricted
manner as the endogenous AFP gene (Krumlauf et al., 1985).
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Chimeric transgenes, in which the repressor/promoter regions and the five-exon
AFP minigene were linked to the Albumin enhancer, were regulated by Zhx2 whereas
transgenes containing the Albumin promoter and Albumin minigene linked to the AFP
enhancers were not. These results indicated that AFP enhancers do not direct AFP
post-natal repression mediated by Zhx2 and, rather, elements contained within the 1 kb
5’-flanking region or within AFP structural gene were required (Camper and Tilghman,
1989). To explore whether sequences within the AFP structural gene are required for
Zhx2 regulation, transgenic mice expressing the AFP 5’-flanking region containing the
E1 and the repressor/promoter regions linked to the mouse major histocompatibility
complex (MHC) class I H-2Dd (AFP-Dd),

were generated.

It was found that the

unrelated gene linked to AFP 5’-flanking region was expressed in the same tissues and
postnatally repressed like the endogenous AFP (Spear, 1994).

Moreover, a similar

chimeric construct in which the Dd gene was linked to the 250 bp AFP promoter and E2
enhancer was not only postnatally repressed but was also responsive to Zhx2 in a
similar manner to endogenous AFP. This indicated that the AFP promoter is sufficient
for conferring Zhx2 regulation (Peyton et al., 2000b).
The studies described above indicated that Zhx2 regulates AFP and H19 genes
through the promoter. However, nuclear run on assays showed that the transcription
rates of H19 gene and AFP transgene were similar between mice that did or did not
express Zhx2. Thus, transcriptional difference can not account for the 10 to 20-fold
difference in adult liver H19 and AFP mRNAs levels. Therefore, Zhx2 was proposed to
regulate target genes at the post-transcriptional level (Vacher et al., 1992). A more
detailed nuclear run-on experiment was performed in our lab using single strand probes
derived from M13 clones. These probes covered the 5’-end, middle and 3’-end of the
mouse AFP and H19 genes in the sense and anti-sense orientations.

Similar

transcription rates were observed for both genes in the presence or absence of Zhx2.
Low levels of antisense transcription were detected, but it was not different between
mice and does not contribute to Zhx2 regulation. Also, there was no significant loss of
signal between the 5’-end probe and 3’-end probes that would indicate early termination
of transcription. These result confirmed the post-transcriptional regulation of AFP and
H19 genes and additionally, demonstrated that neither anti-sense transcription nor
transcription termination are involved in Zhx2 regulation.

Based on data described

above, it is proposed that Zhx2 controls target genes by a mechanism that couples
transcriptional and post-transcriptional steps of gene expression. It is well documented
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using artificially constructed minigenes that promoters influence transcription elongation
and regulate post-transcriptional events such as splicing. Zhx2 regulation of AFP and
H19 may be a natural example of where these events interact to regulate endogenous
gene expression.
More recently, the effect of ZHX2 on AFP expression was studied in human
hepatoma cell lines.

HepG2 and HepG2215 cell lines express low levels of ZHX2

mRNA which correlated with high level of secreted AFP, while SMMC771 and LO2 cell
lines express higher levels of ZHX2 mRNA and lower level of secreted AFP.
Overexpression of ZHX2 in HepG2 cells reduced AFP protein levels in a dosedependent manner by about 25%, whereas, down-regulation of ZHX2 by siRNA in
SMMC771 and LO2 cell lines increased levels of AFP about two-fold without affecting
Albumin levels. These results suggested AFP secretion in different hepatoma cell lines
is inversely correlated with expression of ZHX2. Additionally, HepG2 cells were cotransfected with a ZHX2-expressing plasmid and a reporter construct in which the
luciferase gene was linked to the 269 bp human AFP promoter. Luciferase activity was
reduced by about two-fold upon increased expression of ZHX2. This indicated that
ZHX2 can also repress AFP expression mediated by the AFP promoter in HepG2 cells
(Shen et al., 2008). Similar results were observed with the mouse AFP promoter linked
to luciferase (Yamada, 2009).

Both cell culture and transgenic mice have provided

insight into the AFP cis-acting sequences and factors required for expression and
developmental silencing. However, it is important to note that in cell culture systems the
repression of AFP observed is, in most cases, only two-fold, while in the mouse model,
the presence or absence of Zhx2 results in about 10 to 20-fold difference in AFP
expression. More research must be done to improve the cell culture system to study
AFP regulation by Zhx2 and thus, the mouse model remains an essential tool for
studying developmental repression by Zhx2.
B CELL DEVELOPMENT
B lymphocytes derive from a common lymphoid progenitor cell in the bone
marrow, where resident stromal cells provide the chemokines and cytokines as well
intercellular contact required for survival and proper early stage development of B cells.
This involves productive DNA arrangements of the VHDHJH segments of the
immunoglobulin (Ig) heavy chain locus and the VLJL segments of the κ or λ light chain
loci, allowing the expression of a functional B cell receptor (BCR) complex on the B cell
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surface. The Ig receptor consists of two identical heavy chains and two identical light
chains held together through disulfide bonds to form a membrane-bound IgM (µm), and
together with the Igα and Igβ heterodimer on the B cell surface, delivers intracellular
signaling important for survival and proliferation. Once the IgM is expressed on the B
cell surface, the immature B cells are selected for central tolerance, so B cells that
recognize self-antigens are removed by apoptosis or undergo further light chain
rearrangements, mediated by receptor editing, to reduce potential auto-reactivity.
Immature B cells start to express new adhesion molecules and homing receptors,
becoming a transitional type 1 B cell (T1 B cell). This allows transition of the developing
B cell to the periarteriolar lymphoid sheath in the spleen where local production of B cell
lymphocyte activating factor induces survival and transition to a T2 B cell. At this stage,
B cells migrate to other secondary lymphoid tissues where they become mature naïve B
cells and co-express IgM and IgD on their surface. These B cells are ready to encounter
antigen which will trigger clonal expansion and the differentiation of the B cell into an Igsecreting plasma cell (Kurosaki et al., 2010).
Upon encounter with antigen, B cells can also undergo isotype switching, a
process in which expression of IgM and IgD switch to other Ig classes, IgA, IgG or IgE,
without a change in the antigenic specificity. Isotype switching is regulated by external
signals such as cytokines released by T lymphocytes and it involves irreversible
nonhomologous DNA recombination guided by stretches of repetitive DNA sequences
known as switch regions (SH). The SH regions lie in the intron between the JH gene
segments and the Cµ gene, and upstream of the genes for each other heavy chain
isotype with the exception of the Cδ gene. Unlike IgA, IgG and IgE, co-expression of
IgD along with IgM does not involve DNA rearrangement, instead it involves alternative
splicing of the variable region (VHDHJH) to the Cδ1 exon, resulting in the removal of the
Cµ region in the pre-mRNA (Janeway, 2005; Peterson, 1994b; Peterson, 2007).
Ig heavy chain genes encoding IgM, IgD, IgA, IgG and IgE, have similar gene
structure.

They all encode both membrane-bound and secreted Ig isoforms and

therefore, undergo regulated RNA processing at the 3’ end of the transcript as B cells
mature to plasma cells. In naïve B cells and memory B cells, mRNA encoding the
membrane-associated isoform predominates, while in plasma cells, the mRNA encoding
the secreted form is preferentially expressed. The exclusive expression of the Ig on the
B cell surface, and Ig secretion in plasma cells, is due in part to differences in the
relative expression of the mRNA isoforms but also, to the contribution of additional post-
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translational mechanisms, such as differential intracellular retention and protein
degradation (Peterson, 1994b; Peterson, 2007; Peterson, 2011).
REGULATION OF IgM EXPRESSION
The shift between the membrane-associated (µm) and the secreted (µs) IgM
isoforms observed as B cells differentiate into plasma cells occurs by alternative RNA
processing at the 3’ end of a common precursor RNA (Figure 1-5). The µs mRNA is
produced by cleavage and polyadenylation of the transcript at the proximal (µs) poly(A)
site, while the µm mRNA is produced by splicing between the Cµ4 and M1 exons
followed by cleavage and polyadenylation at the distal (µm) poly(A) site. B cell lines
express roughly similar levels of µs and µm mRNA while plasma cell lines express 10-20
fold more µs mRNA than µm mRNA, so the µs/µm mRNA ratio increases as B cells
progress to plasma cells (Peterson, 2007).
The IgM gene has been extensively studied as a model to better understand the
mechanisms involved in the regulated RNA processing observed during B cell
development. For this purpose, plasmids expressing intact or modified sequences of the
mouse Cµ gene driven by a heterologous promoter have been transiently or stably
transfected into suitable mouse B cell and plasma cell lines, such as M12 and S194,
respectively (Peterson, 2007; Peterson, 2011). The murine B cell line, M12, does not
express endogenous immunoglobulin, while the murine plasmacytoma cell line S194,
expresses only the endogenous IgA gene. The absence of endogenous IgM expression
in these cell lines make them ideal for expression of transfected IgM constructs (Kim et
al., 1979; Hyman et al., 1972). Additionally, when either the wild-type or chimeric IgM
genes are transfected into B cells and plasma cells, the shift in the µs/µm mRNA ratio,
from 1-2 to >10, resembles that observed in the endogenous µ gene when resting B
cells are stimulated into Ig-secreting cells.

These results validate this experimental

system and it has been a valuable tool for understanding the elements required for the
regulated shift in the µs/µm mRNA ratio observed during B cell differentiation to plasma
cells, and it is extensively used in the present study (Peterson, 2007).
Based on deletion, substitution and mutations of other portions of the µ gene
using the approach mentioned above, it was concluded that the strength of the two
competing reactions, the cleavage and polyadenylation at the µs poly(A) site and the
Cµ4-M1 splice, has to be balanced in order for regulation to occur. In the wild-type IgM
gene both the µs poly(A) site and the splice site are suboptimal. Substitution of the µs
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poly(A) site by a stronger poly(A) site and maintaining the suboptimal Cµ4 5’ splice site
predominantly favored µs mRNA in both B cell and plasma cells, thus the regulation was
disrupted. Substitution of the Cµ4 5’ splice site by a consensus splice signal while
maintaining the suboptimal µs poly(A) site exclusively favored the production of µm
mRNA, even in plasma cells. Only when both sequences were replaced with strong
signals was the µs/µm mRNA ratio developmentally regulated (Peterson, 1992; Peterson
and Perry, 1989).
Deletion of a 158 bp NotI-HindIII fragment 50 bp downstream of the µs poly(A)
site decreased the µs/µm mRNA ratio by 3- to 8-fold in B, plasma and non-lymphoid
cells (Peterson et al., 2002). A detailed analysis of the region uncovered the existence
of an RNAPII pause site, with the following features: the fragment enhanced the use of
a weaker upstream poly(A) site when placed between tandem poly(A) sites; it could be
replaced by other known pause sites such as the H3.3 and the MAZ elements and runon assays showed an increase in RNAPII loading about 50 bp downstream of the µs
poly(A) site even when the µs poly(A) was inactivated (Peterson et al., 2002).
Additionally, the µ pause site effect on µs poly(A) site use was lost when it is moved over
100 bp downstream from its original position, although it still induced RNAPII pausing
(Burnside et al., 2011; Peterson et al., 2002).
Other parameters that impact the µs/µm mRNA ratio, without affecting the
developmental regulation between B cells and plasma cells, are the Cµ4-M1 intron size
(Peterson and Perry, 1986; Tsurushita and Korn, 1987) and the Cµ4 exon size (Peterson
et al., 1994). Shortening either Cµ4-M1 intron or the Cµ4 exon favored the splicing
reaction so more µm mRNA was made. Deletion and substitution of different portions of
the µ gene also revealed that there are no gene-specific sequences required for the
regulated µs/µm mRNA ratio shift between B cells and plasma cells. Moreover, nonimmunoglobulin genes (β-globin and Major Histocompatibility Complex H-2Dd) that were
modified by inserting a intronic poly(A) signal, so they could be alternative spliced or
cleaved and polyadenylated at the inserted poly(A) site, were regulated in B cell and
plasma cells like the Ig genes (Peterson, 1994a; Peterson, 2011). This was further
tested in resting and stimulated B lymphocytes derived from transgenic mice expressing
the modified Dd gene. Similarly to the endogenous µ gene, the pA/spliced Dd mRNA
ratio increased as the B lymphocytes were differentiated (Peterson, 2011; Seipelt et al.,
1998).
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These studies indicate that the balanced efficiencies of the competing splice and
cleavage-polyadenylation reactions are critical features for the developmental Ig RNA
processing, and the Cµ4-M1 intron and Cµ4 exon sizes have an effect on the efficiency
of these competing reactions. Consistent with these facts, other immunoglobulin genes
that undergo developmental expression regulation have similar gene structures, where
poly(A) strength and the intron and exon sizes are well conserved (Peterson, 2011).
Because the Ig gene structure rather than specific sequences are important for
regulation, it is likely that the trans-acting factors that regulate the alternative RNA
processing reactions will be involved in regulating the general splicing and/or cleavagepolyadenylation reactions.

In fact, there is evidence that both splicing and

cleavage/polyadenylation activities are different between B cells and plasma cells. To
test whether differences in splicing environment alter µs/splice mRNA ratio, µ gene
constructs were transiently co-transfected with different SR-encoding plasmids in B cell
(M12) and plasma cell (S194) lines. Expression of several SR proteins, SF2/ASF,
SRp30c and SRp55, decreased the µs/splice mRNA ratio, suggesting they enhance the
Cµ4-M1 splice reaction (Bruce et al., 2003). On the other hand, differences in cleavage
and polyadenylation activity were also observed when constructs with tandem poly(A)
sites were expressed in B cell and plasma cell lines. It is also reported that cleavage
and polyadenylation efficiency increases as B cell differentiate to plasma cells (Peterson
et al., 1991).

Therefore, several trans-acting factors involved in either splicing or

cleavage and polyadenylation may be implicated in the µ RNA processing switch. Some
candidates which relative levels differ between B cells and plasma cells have been
studied, Cst64, hnRNP H/H’/F family and U1 snRNP, however their roles in regulating
the µs/splice mRNA ratio are not fully understood (Peterson, 2007; Peterson, 2011).
More recently, the elongation factor ELL2 was reported to be an important factor in
shifting the Ig heavy-chain (IgH) pre-mRNA processing from the membrane associated
form to the secreted mRNA form (Martincic et al., 2009). ELL2, which increases during
B cell differentiation to plasma cells was shown to bind to the IgH promoter and favor the
recruitment of Cst64 to the RNAPII near the 5’ end of the gene. ELL2 expression was
associated with enhanced polyadenylation at the promoter proximal poly(A) site in a
construct with tandem poly(A) sites and also increased exon skipping of the Ed1 splicing
reporter gene. Therefore, it was suggested that ELL2 influences the IgH pre-mRNA
processing by increasing the polyadenylation at the promoter-proximal poly(A) site and
reducing the efficiency of splicing (exon skipping).
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IgM TRANSCRIPTION TERMINATION
Several studies have investigated the transcription termination profiles in the µ-δ
locus by nuclear run-on analysis, using either resting and stimulated B cells or cells lines
that represent different B cell developmental stages. These studies have shown the
transcription unit is gradually foreshortened as B cells progress to plasma cells. In IgM
secreting cells, transcription is terminated predominantly downstream of the µm poly(A),
while in surface-IgM expressing cells, transcription proceeds throughout the δ locus.
The gradual foreshortening of transcription termination through the µ-δ locus observed in
plasma cells, is responsible for the lack of IgD expression. However, it is not likely to be
involved in the increased expression of µs mRNA because most transcripts contain the
Cµ4-M1 splice and thus are able to produce µm mRNA.

Based on the fact that a

functional poly(A) site is required for efficient transcription termination to occur, the
earlier transcription termination observed in plasma cells may be explained by a
developmental increase in efficiency of the µs poly(A) usage (Kelley and Perry, 1986;
Peterson, 2007; Weiss et al., 1989; Yuan and Tucker, 1984).
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Figure 1-1. Transcription coupling with RNA processing. Transcription is a step-wise
process (black print) in which each step is tightly associated with different RNA
processing stage (blue print) as described. Checkpoints at each step (red print) ensure
proper transcriptional regulation and RNA processing. Additional detail is explained in
the text.
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Figure 1-2. Spliceosome assembly. (A) Consensus sequences at the intron-exon
boundaries. (B) Steps involved in spliceosome assembly.
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Figure 1-3. Simplified model of the nonsense mediated decay pathway activation.

27

Figure 1-4. Cleavage and polyadenylation process. (A) Cleavage and polyadenylation
scheme. (B) Sequences involved in cleavage and polyadenylation factor recognition.

28

Figure 1-5. IgM gene structure and alternative RNA processing.
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CHAPTER II

MATERIALS AND METHODS

PLASMID CONSTRUCTION
pGEM-T-CoTC was made by cloning the β-globin CoTC element into the pGEMT easy vector (Promega). The full β-globin CoTC fragment was PCR-amplified with
Asp718 ends from β∆5-7p(A)mut (Dye and Proudfoot, 2001) using the primers CoTCFc/CoTC-R800. The 800bp-PCR product was DpnI-treated and cloned into pGEM-T
Easy vector following manufacturer instructions.
Cµ/CoTC(+), Cµ/CoTC(-), ∆NH/CoTC(+), ∆NH/CoTC(-), ∆AR/CoTC(+) and
∆AR/CoTC(-) (Table 2-1) were made to determine the effect of having a CoTC element
at the KpnI site within the Cµ4-M1 intron on the µm/µs mRNA expression ratio. The 800
bp Asp718-digested fragment from pGEM-T-CoTC was cloned into IgCµ(WT),
IgCµ(∆NH) and Cµ(∆AR), that had been digested with Asp718 and treated with SAP, to
obtain Cµ/CoTC, ∆NH/CoTC and ∆AR/CoTC, respectively. Cµ(WT) refers to the wildtype µ construct; Cµ(∆NH) has a 158 bp deletion between the NotI and HindIII sites
within the Cµ4-M1 intron which contains a RNAPII pause site element (Peterson et al.,
2002); and Cµ(∆AR) contains a 797 bp deletion between the AccI and EcoRV sites in
the middle of the Cµ4-M1 intron (Peterson and Perry, 1986). For each construct, clones
containing the CoTC sequence in either orientation were selected, denoted as (+) when
β-globin CoTC is in 5´-3´orientation and (-) when the β-globin CoTC is in 3´-5´orientation,
to obtain Cµ/CoTC(+), Cµ/CoTC(-), ∆NH/CoTC(+), ∆NH/CoTC(-), ∆AR/CoTC(+) and
∆AR/CoTC(-).
Cµ/CoTC(+)-H and ∆NH/CoTC(+)-H (Table 2-1) were made to determine the
effect of having a CoTC element at the HindIII site on the µm/µs mRNA expression ratio
in presence or absence of the RNAPII pause site element. Cloning the β-globin CoTC at
the HindIII or NotI-HindIII (referred as ∆NH) sites of Cµ required three sequential cloning
steps. The 800 bp Asp718-digested fragment from pGEM-T/CoTC was Klenow treated
to make blunt ends and inserted at either the HindIII or NotI-HindIII sites of pUCPst, also
Klenow-treated after restriction enzyme digestion. pUCPst contains the 2318 bp-PstI
fragment of µ gene spanning the region between the Cµ4 and M2 exons cloned into
pUC9 (Peterson and Perry, 1989). The ApaI-KpnI fragment containing the modified
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sequences was cloned into the ApaI-KpnI-cut pSV2Cµ which contains the 6 Kb BglII
fragment comprising the µ constant region (Peterson and Perry, 1986). The last cloning
step transferred the BamHI-BglII fragment of the modified pSV2Cµ into the BamHI-cut
pIgCµ where an intact µ gene containing the modification could be expressed stably in
lymphoid cell lines such as M12 and S194 cells (Peterson and Perry, 1989).
Cµ/rpI900-H and ∆NH/rpI900-H (Table 2-1) were made to use as intron size
controls by inserting an unrelated sequence with no known CoTC activity, into Cµ. The
rpI900 fragment is a 900-bp BamHI-SmaI fragment from the second intron of the S16
ribosomal protein gene. This fragment was Klenow-treated to make blunt ends and
inserted into the HindIII or HindIII-NotI sites of the µ gene, following the thee-step cloning
procedure described above.
Other plasmid constructs described in previous studies also were used as
controls. These constructs differ in the Cµ4-M1 intron length by deleting or inserting
unrelated sequences (Table 2-1). The ∆NR contains a 351 bp deletion between the
NcoI and EcoRV sites, ∆AN has a deletion of 446 bp between AccI and NcoI sites,
AR/rpI900 has 797 bp deleted between the AccI and EcoRV sites and the rpI900
fragment inserted at the KpnI site, Cµ/rpI900 has the rpI900 fragment inserted at the
KpnI site in the wild-type Cµ gene (Peterson and Perry, 1986).
CELL LINES AND CULTURE CONDITIONS
B Cells:
M12 murine B cells, a lymphoma-derived cell line deficient in IgM expression
when established in culture (Kim et al., 1979), were grown in RPMI 1640 medium
supplemented

with

10%

heat-inactivated

fetal

bovine

serum,

50

U/ml

penicillin/Streptomycin and 50 µM β-mercaptoethanol. The 38C-13 cell line is derived
from a C3H/eB mouse-B cell lymphoma and expresses roughly similar amount of µm
and µs mRNA (Nelson et al., 1983). This cell line was grown in the same medium as
M12 cells.

Plasma Cell lines
The S194 murine plasmacytoma cell line, a myeloid-derived cell line expressing
IgA but defective in IgA secretion (Hyman et al., 1972), was obtained from the American
Type Culture Collection. S194 cells were maintained in Dulbelcco´s modified Eagles
medium (DMEM) supplemented with 10% heat-inactivated horse serum and 50 U/ml
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penicillin/Streptomycin. The D2 cell line is a 38C-13-derived hybridoma cell line actively
secreting IgM (µs mRNA >> µm mRNA) (Nelson et al., 1983) and was propaged in RPMI
1640 medium supplemented with 20% fetal bovine serum.

HEK293 cells
HEK293 cells were obtained from the American Type Culture Collection and
maintained in Dulbelcco´s modified Eagles medium (DMEM) supplemented with 10%
heat-inactivated fetal bovine serum and 50 U/ml penicillin/streptomycin.
DNA PREPARATIONS, PRIMERS AND SEQUENCING
Plasmid DNA used for sequencing or transfections was prepared by cesium
chloride protocol as described by Ausubel et al. (1987). DNA concentration was
quantified by optical density at 260 nm. Primers were purchased from Integrated DNA
Technologies, Inc. (IDT; Coraville, IA).

DNA sequencing was performed by MWG

Biotech (High Point, NC) for sequencing.
DNA TRANSFECTIONS
Stable transfections
M12 B cells and S194 plasma cells were stably transfected by electroporation as
described by Bruce et al. (2003). About 20 µg of PvuI-linearized plasmid DNA were
used for transfecting 5x106 cells that had been washed and resuspended in 0.8 ml of
Opti-MEM-I+GlutaMAX-I (GIBCO).

Cells were electroporated at 250 volts and a

capacitance of 960 (BioRad) and allowed to recover overnight before being selected with
G418 at 300 µg/ml for M12 and 600 µg/ml for S194. Cells were collected after at least
2-3 weeks of G418 selection and RNA was extracted.

Calcium phosphate transient transfections
HEK293 cells were transiently transfected by the calcium phosphate protocol
described by Spear and Tilghman (Spear and Tilghman, 1990).

Briefly, two 80%

confluent plates of cells were split into 6 plates the day before transfection. 15 µg of
plasmid DNA resuspended in 450 µl of 250 mM CaCl2 were added dropwise with slow
bubbling to 500 µl of 2X HBS (280mM NaCl, 50 mM HEPES, 1.5 mM NaPO4, pH 7.1).
The precipitate was allowed to sit for 30 minutes at room temperature and then added to
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a plate of HEK293 cells. After 6 hours, the cells were rinsed and incubated with fresh
media for 48 hours before being collected for nuclear extract preparation.
RNA PREPARATIONS
Total RNA extraction
Total RNA from 1×107 stably transfected M12 B cells or S194 plasma cells was
extracted with Trizol reagent following manufacturer instructions (Invitrogen). Total RNA
from mouse liver was obtained by homogenization of about 100 mg of liver sample
followed by two sequential Trizol reagent extractions.

The RNA concentration was

quantified by optical density at 260 nm.

Nuclear RNA extraction from B cells and plasma cells
Nuclear RNA from 38C-13 and D2 cells was isolated by the hot phenol method
from citric acid-purified nuclei (Schibler et al., 1975).

Briefly, 1-2 ×108 cells were

resuspended in 10 ml of cold 5% citric acid, homogenized and then centrifuged over 10
ml of 30% sucrose/5% citric acid cushion at 1000×g for 10 minutes at 4°C. The pellet
was resuspended in 10 ml of cold 10mM sodium acetate/10 mM NaCl and centrifuged at
2000 rpm for 5 minutes. The pellet was resuspended in 1 ml of 50 mM sodium acetate
and RNA was extracted by the hot phenol method. Briefly, 10 ml of 50 mM sodium
acetate/1% SDS was added while gently vortexing the sample. The suspension was
extracted with an equal volume of hot phenol saturated with 50 mM sodium acetate,
incubated for 15 minutes at 68°C with intermittent shaking and then chilled on ice for at
least 5 minutes. After centrifugation, a second extraction was performed, followed by a
final extraction with chloroform:isoamylic alcohol (24:1). RNA was precipitated with 1/10
volume of 3 M sodium acetate and 2.5 volumes of ethanol. For RT-PCR analysis, 100200 µg of nuclear RNA was further treated with Trizol reagent in order to eliminate
remnant DNA contamination.

Cellular RNA fractions from mouse liver
Mouse liver was homogenized in 10 ml of Buffer I (0.25 M sucrose, 60 mM KCl,
15 mM NaCl, 15 mM Hepes pH7.4, 2 mM EDTA, 0.5 mM EGTA, 0.15 mM spermine, 0.5
mM spermidine and 14 mM β-mercaptoethanol) in a Dounce homogenizer using 18
strokes with pestle A and 18 strokes with pestle B. Homogenate was layered on 10 ml
of Buffer II (same as buffer I but containing 0.75 M sucrose) and spun at 1000 ×g for 10
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minutes at 4 ºC.

Cytoplasmic fraction corresponding to the pinkish top faction was

saved for cytoplasmic RNA extraction, while the interface phase was discarded. The
nuclear pellet was resuspended in 3.2 ml of Buffer III (same as buffer I but containing 2
M sucrose) and layered over 1 ml cushion of Buffer III, then spun at 33000 rpm for 1 h at
4 ºC in a Beckman Coulter “Optima” ultracentrifuge (SW55 Ti rotor) for nuclei
purification. Chromatin-soluble and chromatin-insoluble fractions were obtained from
purified nuclei as described by Pandya-Jones and Black (Pandya-Jones and Black,
2009). Briefly, nuclei were resuspended in 400 µl of glycerol buffer (20 mM Tris pH 7.9,
75 mM NaCl, 0.5 mM EDTA, 0.85 mM DTT, 50% glycerol and proteinase inhibitors) and
400 µl of urea lysis buffer (20 mM HEPES pH7.6, 1 mM DTT, 7.5 mM MgCl2, 0.2 mM
EDTA, 0.3M NaCl, 1M Urea, 1% NP-40) was added, mixed and incubated for 10
minutes on ice.

The nuclear soluble fraction is recovered from the supernatant by

centrifugation at 14000 rpm in a microcentrifuge for 3 minutes at 4ºC, and used for RNA
extraction.

The insoluble pellet was washed with 400 µl 1X PBS/1mM EDTA and

resuspended in 100 µl DNase buffer containing 10 U of RNase-free DNase (Promega).
After 5 minutes at 37ºC, RNA was extracted with Trizol reagent with following
modifications: the DNase-treated insoluble fraction was incubated with Trizol reagent at
50ºC for about 5 minutes, 200 µl of chloroform was added and the samples were
centrifuged 15 minutes at 11500 rpm in a microcentrifuge.

The supernatant was

transferred to a new tube and extracted with phenol/chloroform and ethanol precipitated.
Cytoplasmic and nuclear soluble fractions were treated with proteinase K prior to RNA
extraction with Trizol as described for the nuclear insoluble RNA fraction.
Cytoplasmic A+/A- RNA extraction
Cytoplasmic RNA was diluted to <500 µg/ml in sterile buffer E (0.1 M Tris, 1 M
EDTA and 0.1% SDS) and passed over oligo-dT columns. The A- RNA fraction was
recovered from the flow-through by ethanol precipitation. The A+ RNA fraction was
eluted with Buffer A (0.1 M Tris, 1 mM EDTA, 0.1% SDS and 0.2 M NaCl), ethanol
precipitated and resuspended to 0.5 µg/µl..
RNA ANALYSIS
S1 nuclease protection assay
Expression of the exogenous IgM gene was analyzed by the S1 nuclease
protection assay utilizing a 3’ end-labeled probe that differentiates cleaved and
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polyadenylated µs mRNA from spliced µm mRNA (Peterson et al., 2002; Peterson and
Perry, 1989). The probe corresponds to a 640 bp region containing the Cµ4 exon and
part of the intron downstream of the µspA, as well about 30 bp of unrelated sequence
(see Figure 3.2). The 640 bp probe was PCR amplified from 100 ng of any Cµ plasmid
DNA with primers “Pst-T” and “Hind” (Table 2.2) for 30 cycles of 1 minute at 94°C, 2
minutes at 55°C and 2 minutes at 72°C. The PCR product was purified using the QIAEX
II desalting and concentrating DNA protocol following manufacturer instructions, and 200
ng of PstI-digested fragment was 3’-end labeled using the Klenow fragment of DNA
polymerase I and [α-32P]-dCTP. The 3´end-label PCR product was purified through a
Centri-Spin-20 column (Princeton Separation, N.J) and its specific activity (cpm) was
determined in a scintillation counter.
A total of 100 µg of RNA containing 10 µg of either M12 or S194 RNA and carrier
RNA were precipitated along with 20,000 cpm of 3´-end-labeled probe. The pellet was
resuspended in 50 µl of hybridation solution (80% formamide, 0.6 M NaCl, 10 mM
PIPES, 1mM EDTA) and incubated overnight at 50°C after denaturation for 15 minutes
at 80°C. The S1 nuclease digestion was carried out by adding 450 µl of S1 buffer (3 mM
Zinc acetate, 30 mM sodium acetate and 250 mM NaCl) and 60 units of S1 nuclease
(Invitrogen), incubating at 37°C for 30 minutes. Protected fragments were extracted with
chloropane, precipitated with ethanol and analyzed on a 6 % denaturing polyacrylamide
gel (6 % acrylamide/bis-acrylamide, 7 M urea) at 350 V for 1 hour. The dried gel was
quantitated using Phosphorimage analysis and ImageQuant 5.0 (Molecular Dynamics).

In Vitro transcription
To synthesize a control RNA for reverse transcriptase (RT) reactions, a 2976-bp
EcoRV fragment of µ gene was subcloned into pGEM4. This fragment contains about
594-bp upstream of the M1 exon (including the KpnI site) and 1900-bp downstream of
µm pA.

This fragment was in vitro transcribed from pGEM-RV using SP6 RNA

polymerase (Promega) and the Ampliscribe transcription kit (Epicentre) following the
manufacturer instructions.

Briefly, 10 µg of pGEM-RV was linearized with BamHI

followed by chloropane extraction and ethanol precipitation.

The pellet was

resuspended in water at 1 µg/µl and 2 µg of the BamHI-linearized pGEM-RV was in vitro
transcribed by incubation at 37°C for 90 minutes in presence of 10 mM DTT, 80 U of
RNaseout (Invitrogen), 0.5 mM of each rNTP and 17 U of SP6 (Promega). The sample
was treated with 2.5 U of RQ1 DNase I (Promega) for 15 minutes at 37°C follow
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chloropane extraction and ethanol precipitation. The pellet was resuspended in 6 µl of
water and 2 µl was electrophoresed on a 1 % agarose formaldehyde gel and visualized
by ethidium bromide staining to ensure it was intact. One µl of a 1:1000 dilution of the in
vitro transcribed RNA was used for the reverse transcription reactions with a µ sequence
specific primer and 1 µl of the 1:10 diluted RT reaction was used for PCR reactions.

Reverse Transcriptase-PCR (RT-PCR)
One to two µg of total RNA was reverse transcribed with hexamer random
primers (Invitrogen) or a gene-specific primer using the Omniscript RT Kit (QIAGEN)
following manufacturer instructions.

cDNA was PCR amplified using 1-5 µl of the

(undiluted or 1:5 diluted) RT reaction. To ensure the reactions were within the linear
amplification range, PCR products were collected at different cycle numbers.

PCR

products were analyzed on agarose gels containing ethidium bromide, photographed
and when required, specific PCR product bands were quantified from the digital images
using ImageQuant 5.0 (Molecular Dynamics). All PCR reactions were performed with
controls in which the reverse transcriptase was omitted from the reaction; all the RT(-)
reactions were blank, indicating there was no DNA contamination in the RNA samples
(data not shown). The images were often inverted for presentation in the figures.
For radioactive PCR, 40 ng of reverse primer was 5’-end labelled with γ-32P-ATP
and polynucleotide kinase. The 5´end-labeled primer was eluted through a Centri-Spin10 column (Princeton Separation, N.J) and its specific activity (cpm) was determined in a
scintillation counter. PCR reactions were performed as usual but in 25 µl final volume
and containing 0.5 µl of 5’-end labelled primer and 5 µl of RT reaction. PCR products
were ethanol precipitated, resuspended in 5 µl of S1 loading buffer (80% formamide, 1
mM EDTA, 0.1% bromophenol blue, 0.1% xylene cyanol) and analyzed on a 6% or 8%
denaturing polyacrylamide gel (6-8% acrylamide/bis-acrylamide, 7 M urea). The PCR
product bands were visualized from the dried gels using phosphorimage analysis.

3´-Rapid amplification of cDNA-end by PCR (3’-RACE)
One µg of total RNA was reverse transcribed with a tagged-poly-dT primer (RTRACE primer) using the Omniscript RT Kit (QIAGEN) following manufacturer
instructions. Five µl of synthesized cDNA was PCR amplified using a reverse primer
targeting the 3´-end tag (3´RACE-1 primer) and a forward primer complementary to the
Cµ3 exon (Cµ3T primer) for 35 cycles of 94°C for 1 minute, 56°C for 1 minute and 72°C
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for 2 minutes. 5 µl of the PCR product was submitted to a nested PCR with the
“3´RACE-1” primer and a forward primer complementary to the Cµ4 exon (Apa primer)
for 35 cycles of 94°C for 1 minute, 52°C for 1 minute and 72°C for 2 minutes. Ten to
twelve µl of PCR product were digested with 5 units of either NheI (Invitrogen) or SpeI
(NEB) overnight at 37°C and digested and undigested samples were visualized by
ethidium bromide staining in either 1.8% agarose gels or 8% non-denaturing
polyacrylamide gels.
TRANSGENIC MICE
Transgenic mice expressing the TTR-Flag-Zhx2 were generated in a (C57BL/6 ×
C3H) background by the University of Kentucky Transgenic Mouse Facility. Transgenic
founders were bred to BALB/cJ mice and offspring were screened by PCR using DNA
extracted from tail biopsies for the presence of the TTR-Flag-Zhx2 transgene and
primers TTR and H1R. The endogenous Zhx2 allele was assessed with primers Afr1,
Afr2 and ETn3Flank. Nuclear extracts or RNA were prepared from liver of 3 week old or
older littermate with or without the Flag-Zhx2 transgene.
Transgenic mice expressing the AFP minigenes were generated in a (C57BL/6 ×
C3H) background by the University of Kentucky Transgenic Mouse Facility. AFP cDNA
and genomic minigenes were jointly constructed in the Peterson and Spear labs. The
AFP minigenes consist of the AFP exon 1 to exon 3 fused to the last two exons, exon 14
and exon 15, in its genomic (intron containing) or cDNA (no introns) forms. An 18 bp
oligonucleotide was inserted into the Bsu36I site in exon 15 to distinguish the transgene
form the endogenous gene. The minigenes were linked to the AFP enhancer II and
either the AFP 250 bp promoter or 1 kb AFP promoter/repressor regions. Independent
founders were crossed to BALB/cJ and two F1 from each founder were backcrossed to
BALB/cJ. F2 offspring were screened by PCR using DNA extracted from tail biopsies.
Presence of 250-AFP minigenes were analyzed with primers AFP120+165R and
AFPE2, the 1kb-AFP minigenes with primers E3F and E15R and presence of the mutant
or wild-type Zhx2 allele with primers Afr1, Afr2 and ETn3Flank. To determine Zhx2
regulation of AFP minigenes, liver RNA was prepared from F2 transgenic mice and
analyzed by RT-PCR with primers E3F or E14E15-F and E15R.
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PROTEIN PREPARATION AND ANALYSIS
Nuclear extract preparation from mouse liver
Nuclei from mouse liver were purified following the two sequential sucrose
cushion procedure as described in the cellular RNA extraction section. Purified nuclei
obtained from two mouse livers were resuspended in 900 µl of low-salt buffer (20 mM
HEPES pH 7.9, 25% glycerol, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT and
proteinase inhibitors) using a 7 ml Dounce homogenizer and pestle B. Equal volume of
high-salt buffer (20 mM HEPES pH 7.9, 800 mM KCl, 25% glycerol, 1.5 mM MgCl2, 0.2
mM EDTA, 0.5 mM DTT and proteinase inhibitors) was added in a dropwise fashion to
the nuclei suspension while mixing with the pestle B. The extract was incubated for 30
minutes at 4ºC with gentle mixing and transferred to a 2 ml microcentrifuge tube.
Nuclear extract was obtained by centrifugation at 21,000×g for 30 minutes at 4ºC.
Aliquot of supernatants (NE) were quickly frozen in liquid nitrogen and storage at -80ºC.
Pellets were resuspended in 900 µl of 8M urea and 900 µl of 2X loading buffer (125 mM
Tris-HCl pH 6.8, 4% SDS, 20% glycerol, 0.02% bromophenol blue, 0.2 M DTT) and
incubated for 4-5 minutes in a boiling water bath. Total nuclei suspension in low-salt
buffer, nuclear extract and suspended pellet were analyzed by 8% SDS-PAGE,
transferred to PVDF membrane and blotted with anti-Zhx2 and/or anti-Flag antibodies.

Nuclear extract preparation from HEK293 cells
HEK293 cells transiently transfected with a Flag-Zhx2-expressing plasmid were
harvested, washed with PBS (4.3 mM Na2HPO4, 1.4 mM KH2PO4, 137 mM NaCl, 2.7
mM KCl, pH 7.4) and prepared nuclear extract using the NE-PER nuclear and
cytoplasmic extraction reagent (Thermo Scientific) following the instruction manual.
Total protein was determined by BCA protein assay and 2.5 to 5 µg of total protein was
used as positive control in Western blot analysis with anti-Flag or anti-Zhx2 antibodies.

Flag-tagged Zhx2 immunoprecipitation
Immunoprecipitation was performed by batch absorption following the instruction
manual of the anti-Flag M2 affinity gel (Sigma).

Nuclear extracts (100 µg) were

resuspended in lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1%
Triton X-100) up to a final volume of 500 µl and incubated overnight with 10 µl of packed
volume of beads previously equilibrated with TBS. The beads were washed three to four
times with 500 µl of TBS (50 mM Tris-HCl pH 7.4, 150 mM NaCl) and elute with 20 µl of
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2X loading buffer incubated 4 minutes in boiling water bath. Beads were collected by
centrifugation at 7000×g for 1 minute and the eluate was analyzed by Western blot.

Western blotting
Protein samples from total nuclei suspension, nuclear extracts or insoluble
pellets were fractionated on 8% SDS-PAGE and electro-blotted to PVDF (Polyvinylidene
fluoride) membrane (Immobilon-P, Milipore) as described by Ausbel et al. (Ausubel et
al., 1987). Filters were blocked 2 hours or overnight with blocking buffer (20 mM TrisHCl pH 7.6, 140 mM NaCl, 0.1 % Tween-20 and 5% non-fat dry milk). Membranes were
was incubated 2 hours at room temperature or overnight at 4ºC with primary antibody
diluted in blocking buffer and then washed 4 times with TBST (20 mM Tris-HCl pH 7.6,
140 mM NaCl, 0.1 % Tween-20). Membranes were incubated with secondary antibody
2 hours at room temperature, washed 4 times with TBST and bands were visualized by
enhanced chemiluminescence (Pierce). Primary antibodies used: monoclonal mouse
anti-Flag M2 (Sigma) 1:500 dilution; polyclonal rabbit Anti-Zhx2 (Bethyl laboratories)
1:2000 dilution. Secondary antibodies used: goat anti-mouse IgG-HRP (sc-2031) 1:4000
dilution and goat anti-rabbit IgG-HRP (sc-2004) 1:8000 dilution.

BCA protein assay
Total protein concentration from nuclear extracts was determined by BCA (PIERCE),
following the instruction manual.
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Table 2-1: Plasmid constructs used in Cµ study.
Plasmid

Construct

pGEM-T-CoTCa

β-globin CoTC (800 bp) PCR product cloned into pGEM-T

Cµ c

Intact Ig µ gene in the pR-SP6 plasmid backbone

∆NH d

∆AN b

Intact Ig µ gene containing a 158 bp deletion of the pause element
between NotI and HindIII sites
Intact Ig µ gene containing a 797 bp deletion between AccI and EcoRV
sites
Intact Ig µ gene containing a 351 bp deletion between NcoI and EcoRV
sites
Intact Ig µ gene containing a 446 bp deletion between AccI and NcoI
sites

∆AR/pBR403 b

403 bp fragment from pBR322 inserted in the KpnI site of ∆AR

∆AR/rpI900 b

900 bp fragment from the intron of the S16 ribosomal protein gene
(rpI900) inserted at the KpnI site of ∆AR

Cµ/rpI900 b

rpI900 fragment inserted at the KpnI site of Cµ

∆AR b
∆NR b

Cµ/CoTC(+)a
Cµ/CoTC(-)a
∆NH/CoTC(+)a
∆NH/CoTC(-)a
∆AR/CoTC(+)a
∆AR/CoTC(-)a
Cµ/CoTC-Ha
∆NH/CoTC-H a

β-globin CoTC inserted in 5’-3’ orientation 1200 bp downstream of µspA
(KpnI site) of Cµ
β-globin CoTC inserted in 3’-5’ orientation 1200 bp downstream of µspA
(KpnI site) of Cµ
β-globin CoTC inserted in 5’-3’ orientation 1042 bp downstream of µspA
(KpnI site) of ∆NH
β-globin CoTC inserted in 3’-5’ orientation 1042 bp downstream of µspA
(KpnI site) of ∆NH
β-globin CoTC inserted in 5’-3’ orientation 403 bp downstream of µspA
(KpnI site) of ∆AR
β-globin CoTC inserted in 3’-5’ orientation 403 bp downstream of µspA
(KpnI site) of ∆AR
β-globin CoTC inserted in 5’-3’ orientation 200 bp downstream of µspA
(HindIII site) of Cµ
β-globin CoTC inserted in 3’-5’ orientation 50 bp downstream of µspA
(HindIII site) of ∆NH

Cµ/rpI900-H a

rpI900 fragment inserted 200 bp downstream of µspA (HindIII site) of Cµ

∆NH/rpI900-H a

rpI900 fragment inserted 50 bp downstream of µspA (HindIII site) ∆NH

a

This work
Peterson and Perry (1986)
c
Peterson and Perry (1989)
d
Peterson et al (2002)
b
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Table 2-2: Oligos used for reverse transcriptase and PCR reactions in Cµ study.
CoTC-Fc (#342): 5’ ACTTAGGTACCATAGTGTTACCATCAACCACC 3’
CoTC-R800 (#344): 5’ ACAATGGTACCTCCCACCCCCAACCCCT 3’
Hind (#4): 5’ ATATGTGCCTGAATGCTGCC 3’
Pst-T (#264): 5’ TGGTGAAGGGCTTCTCTCCTG 3’
RT-RACE (#48): 5’ AGAGAATTCACCGGATCCTACCCGGGTTTTTTT 3’
3´RACE-1(#51): 5’ GAGAATTCACCGGATCCTAC 3’
Apa (# 7): 5’ TATGTGACCAGTGCCCCGAT 3’
Cµ3T (#86): 5’ TGACTCACAGGGATCTGCCT 3’
C4B (#274): 5’ CATTCCTCCTCTGTCACAGTCAGG 3’
CµpA-T (#242): 5’ CCTGGGTGTCCAGTTGCTCTGT 3’
432AS (#246): 5’ TGTACCTTTGTCTGTGTGTCCATGA 3’
1528AS (#248): 5’ GGCAGACTCAGGAACTGTGGCA 3’
Kpn-T (#265): 5’ GATCAGAGATCCCAATAAATGCCC 3’
Kpn-B (#278): 5’ AAGGACTCGGACATCTCATGACTTT 3’
M1-B (#277): 5’ CAAAGCCTTCCTCCTCAGCATT 3’
M2-T(#279): 5’ TGTACAATCTGAAGCAATGTCTGGC 3’
M2-B (#280): 5’ CAGATAATCCTTGGGCTGTCAACA 3’
469-T (#281): 5’ TGGGTGTGCCTTTGGGGAGT 3’
469-B (#282): 5’ GCCTTTATCTGTCCTCGAGTGACT3’
473AS (#546): 5’ AGGGACCATCACCAAGGTGC 3’
982AS (#548): 5’ TAGCTCTGAGGTCATGGCGGGT 3’

Table 2-3: Oligos used for PCR reactions in Zhx2 study.
TTR (#110S): 5’ TGTTCCAGAGTCTATCACCG 3’
B-ActF (#131): 5’ GTGGGCCGCTCTAGGCACCA 3’
B-ActR (#132): 5’ CGGTTGGCCTTAGGGTTCAGGGGGG 3’
L30R (#138): 5’ CCTCAAAGCTGGACAGTTGTTGGCA 3’
AFPE12A (#267): 5’ TGAGCTTGGCACAGATCCTTGTGGA 3’
E1E5H19-F (#322): 5’ TCCAGAGTCCGTGGCCAAGGAGG 3’
E1E5H19-R (#323): 5’ TGGATTCTCAGGGGTGGGTGGGT 3’
E2E3-F (#324): 5’ TCCACGTTAGATTCCTCCCAGTGCG 3’
E2E3-R (#325): 5’ TGTTCACTTCCTCCTCGGTGGCTTC 3’
E5E6-R (#327): 5’ TTGCCTGGAGGTTTCGGGATCC 3’
E10E11-F (#330): 5’ TGCAGAAACACATCGAGGAGAGCCA 3’
E10E11-R (#331): 5’ CGTGGAGGCAATGCTCACCATCTTC 3’
E14E15-F (#334): 5’ GGTCCAAAGTTGATTTCCAAAACTC 3’
E13E15-F (#337): 5’ GCCAAAAGGCTCACACCAAAGAGTC 3’
E11E12F (#373): 5’ TTATTGGTTACACGAGGAAAGCCC 3’
E12E13-FB (#377): 5’ GCCGACATTTTCATTGGACATTTGT 3’
E12E13-RB (#378): 5’ CAGACTTCCTGGTCCTGGGCTTT 3’
Afp3’-F (#396): 5’ TTGATTTCCAAAACTCGTGATGC 3’
Afp3’-R1 (#397): 5’ GAAATCTCACATGGACATCTTCACC 3’
Afp3’-R2 (#398): 5’ TCAGAGGAGAAGTGGAATGGTGA 3’
H1R (#405S): 5’ CCCATAGATTTCACCTCAACC 3’
Gpc3 U-2 (#423): 5’ TGACCGTGACCTTGAGCGTC 3’
nest12-13BF (#432): 5’ TTCTCCCAGTTTTCTTCACCCCAG 3’
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nest12-13BR (#433): 5’ AACCCTAGCAGCCATCCTCAG 3’
Gpc3E7-U (#438): 5’ ACGGGATGGTGAAAGTGAAGAAT 3’
Gpc3E8-L (#440): 5’ CGCTGTGAGAGGTGGTGA 3’
H19Ex2-L (#443): 5’ AAGAAGGCTGGATGACTG 3’
S-H19 (#463S): 5’ CGTTCTGAATCAAGAAGATGCTGC 3’
AS-H19 (#464S): 5’ TTTGAGTCTCTCAAGCAAGGAAGG 3’
E1F (#499): 5’ GTGAAGGAACCAGCAGCCATGA 3’
E3F (#500) 5’ AATGACTAGCGATGTGTTGGCTGC 3’
E14R (#501): CGCCCAAAGCATCACGAGTTT 3’
E15R (#502) 5’ TTCCTAAGGCAAGCTTCGAGGCT 3’
U6F (#579): 5’ GTGCTCGCTTCGGCAGCACATATA 3’
U6R (#580): CGAATTTGCGTGTCATCCTTGCG 3’
L30F2 (#581): 5’ TGTCCCGCACCTAAGGCAGGAAGAT 3’
i9-F (#596): 5’ AAGGCAAAATCTCCTGTCCAGTGG 3’
i10-R (#597) 5’ GGTTTGGGGAACCCGAAGTCAAT 3’
i10-F (#598) 5’ TCAAGGAAGAGCTAAGGTTGGGAGG 3’
i11-R (#599) 5’ TTTGAGAAGGACAGAACGCCTGGC 3’
i2-F (#600) 5’ CTGAGTGACTCGAACCCAGTTTCCC 3’
i2-R (#601) 5’ CTGGAACTCCAGTCAATGTCAAGGC 3’
i3-R (#602) 5’ GGCGGGATTCCAGAACTAATCG 3’
i5-R (#605) 5’ CCCACAGGAGGCACATTTCTGC 3’
i1-F (#607) 5’ TGTGAGGGAGCCAAGTAGTAAGGG 3’
E5-F (#608) 5’ TGCCCCAGCCATTCTGTCCT 3’
Z2HD1-F (#1017S): 5’ TCCCCGTCCCGCTGAATACT 3’
Z2HD1-R (#1018S): 5’ TGTGCTCCTCTGGGTGTTTG 3’
Gpc3URT (1031S) 5’ CTCCCAGCAACGCCAATATAGATC 3’
Gpc3LRT (1032S) 5’ CTGATTCTTCATCCCGTTCCTTGC 3’
H19Ex2-U (#1128S) 5’ ACAGAAGGGCAGTCATCCAG 3’
H19Ex3-L2 (#1129S) 5’ CCAGAGAGCAGCAGAGAAGT 3’
H19Ex3-L3 (#1131S) 5’ GTTCAAGGTAGGGGGAGGAG 3’
Afr1 (#1143S) 5’ AACCCAAGTAGCAAGTGAGTGGTG 3’
Afr2 (#1144S) 5’ ATCTCTGGTCCAGTAGAAAGGTGC 3’
ETn3Flank (#1259S) 5’ CCTATCTTGGTACCCTGATCAAGC 3’
AFP120+165R (#1276S) 5’ CCTTACGTTGAAGTTAGGCAA 3’
AFPE2 (#1280S) 5’ GATCTGGATCCGGGGAAATAATCT 3’

Copyright  Lilia M. Turcios 2011
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CHAPTER III
AFP SPLICING REPRESSION BY ZHX2

INTRODUCTION
That transcription and post-transcriptional events are closely associated is
suggested by interactions between components involved in transcription initiation,
elongation and termination with those involved in RNA processing (capping, splicing and
cleavage and polyadenylation). Coupling transcription with RNA processing is mediated,
at least in part, by the C-terminal domain (CTD) of the RNAPII largest subunit, which
contains multiple heptapeptide repeats that are targets of regulated phosphorylation.
Dynamic changes in CTD phosphorylation are involved in modulating recruitment of
factors required for elongation and RNA processing in a temporal-spatial manner.
During transcription initiation, the RNAPII CTD is phosphorylated at serine 5 of the
heptapeptide (S5), resulting in recruitment of DSIF and NELF to the transcription
complex (Figure 1-1). This induces a promoter proximal pausing that allows binding of
capping enzymes. Pausing is relieved by phosphorylation of the RNAPII CTD at serine
2 (S2), mediated by recruitment of pTEFb to the elongation complex.

This causes

dissociation of NELF and transcription elongation proceeds (Bentley, 2002; Bres et al.,
2008; Mandal et al., 2004; Sims et al., 2004b). Although under certain conditions, it has
been reported that RNAPII elongation could proceed in the absence of pTEFb, the
coupling of transcription with RNA processing is disrupted, giving rise to full-length RNA
transcripts that are quickly degraded (Hargreaves et al., 2009). Such is the case of
primary response genes in unstimulated macrophages. Soon after activation, pTEFb is
recruited to the elongation complex and RNA processing is reestablished to allow rapid
production of mature mRNA (Hargreaves et al., 2009). Additionally, promoter structure
has also been implicated in coupling transcriptional and post-transcriptional events to
control gene expression.

Studies with reporter minigenes containing the alternative

exon (E33 or EDI) of the fibronectin (FN) gene showed that FN and CMV promoters
induced 10 times higher inclusion of the exon E33 compared to the α-globin promoter
(Cramer et al., 1999; Cramer et al., 1997; Kornblihtt, 2005, 2006). Therefore, posttranscriptional events can be modulated by altering the elongation properties of the
RNAPII in the pre-initiation complex. This may result in changes in elongation rates or
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recruitment of RNA processing factors and ultimately may have effect on the fate of the
nascent transcript and regulate gene expression (Kornblihtt, 2005).
Expression of the AFP gene is developmentally regulated. It is expressed at high
levels in fetal liver and dramatically repressed after birth. Interestingly, AFP expression
is reactivated in hepatocellular carcinomas and during liver regeneration. Because of
this characteristic pattern of AFP gene expression, it has become an important model for
liver-specific gene expression during liver development, liver regeneration and disease
(Spear et al., 2006). The first information about the mechanism of AFP repression was
obtained by screening adult serum AFP levels of different inbred mouse strains (Olsson
et al., 1977). All the strains expressed low serum levels of AFP with the exception of
BALB/cJ mice that expressed about 10 to 20-fold higher levels than the other mouse
strains analyzed. Post-natal persistence of AFP expression in BALB/cJ mice is due to a
mutation in the Zinc-fingers and homeoboxes 2 (Zhx2) gene (Blankenhorn et al., 1988;
Olsson et al., 1977; Perincheri et al., 2005), a member of a small family of proteins that
contains two zinc fingers and four or five homeodomains (Spear et al., 2006). Analysis
of the BALB/cJ Zhx2 allele revealed the presence of a mouse endogenous retrovirus
(MERV) element that interferes with proper splicing of the Zhx2 transcript,
downregulating its expression in this mouse strain (Perincheri et al., 2008). Lower Zhx2
levels in adult BALB/cJ liver correlate with increased accumulation of AFP and H19
mRNA levels, indicating the role of Zhx2 in repressing expression of these genes after
birth.

Other Zhx2 target genes identified are Gpc3 (Morford et al., 2007) and Lpl

(Gargalovic et al., 2010) Both showed developmental expression patterns similar to the
AFP and H19 genes, high in fetal liver, repressed after birth and reactivated in liver
cancer and during regeneration (Gargalovic et al., 2010; Morford et al., 2007; Spear et
al., 2006).
Transgenic mouse studies using minigenes or other reporter genes linked to
different portions of the AFP 5’ flanking sequences have been used as a strategy to
better understand the mechanism of AFP repression mediated by Zhx2. The 250 bp
AFP promoter was sufficient to confer Zhx2 regulation to a linked reporter gene (H-2Dd)
suggesting that Zhx2 acts at transcriptional level (Peyton et al., 2000a).

However,

transcriptional rates on the AFP and H19 genes, measured by nuclear run-on assays,
were the same in the presence or absence of Zhx2 expression, indicating that Zhx2 may
act at post-transcriptional level (Morford; Vacher et al., 1992). Based on these results, it
was proposed that Zhx2 controls accumulation of mRNA levels of targets genes by a
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mechanism that couples transcription and post-transcriptional events (Peyton et al.,
2000a). Therefore, we explored splicing as possible post-transcriptional step involved in
Zhx2 regulation and indeed, we found that splicing of AFP was repressed in the
presence of Zhx2. We further investigated whether introns are required for splicing
regulation and whether alternative splicing plays a role in AFP post-natal repression
mediated by Zhx2. We also analyzed the splicing efficiency of the H19 and Gpc3 genes,
two other Zhx2 target genes. Preliminary results found no evidence of splicing inhibition
in these genes in response to Zhx2. To investigate possible factors controlled by Zhx2
that are involved in coupling transcription and RNA processing, we intend to purify and
identify proteins that interact with Zhx2. Toward this end, we initiated optimization of
nuclear extracts preparation and immunoprecipitation assays that eventually will lead to
purification of the Flag-tagged Zhx2 and its interacting proteins.
RESULTS
AFP splicing repression mediated by Zhx2
Based on the preliminary data described above, it was proposed that Zhx2
regulates AFP expression through a post-transcriptional mechanism controlled by the
AFP promoter. To determine what post-transcriptional step is involved in that regulation,
splicing efficiency across the AFP gene was analyzed first. Total liver RNA from adult
littermate mice with or without the Flag-tagged Zhx2 transgene was utilized for cDNA
preparation using random hexamers. PCR amplification was performed with sets of
primers spanning several exon-exon boundaries throughout the AFP gene (Figure 3-1).
Data from the PCR reactions diagrammed in Figure 3-1, along with the expected sizes
for the unspliced and/or spliced AFP transcripts are shown in Figure 3-2. Ribosomal
protein L30 (rpL30) was used as an expression control. Negative controls without RT
enzyme were performed and no signal corresponding to PCR products for L30, H19 or
AFP E10-E11 were observed, indicating there was no DNA contamination (Figure 3-2).
When primers targeting several exon-exon regions was performed (Figure 3-2, top
panels: AFP E2-E3, AFP E5-E6, AFP E10-E11, AFP E12-E13, AFP E14-E15), samples
from animals expressing Flag-Zhx2 showed lower accumulation of spliced mRNA than
that observed from samples of animals not expressing Flag-Zhx2.

This result is

consistent with previous data that showed AFP and H19 mRNA accumulated to higher
levels in BALB/cJ mice (no Zhx2 expression). Interestingly, PCR analysis of AFP E10E11, AFP E12-E13 and E14-E15 (Figure 3-2, top panels of AFP E10-E11, AFP E12-E13
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and AFP E14-E15) showed that in the presence of Zhx2, bands corresponding to
unspliced RNA were detected with higher intensity than those observed in the absence
of Zhx2. This suggested that AFP splicing efficiency across multiple exons within the 3’end of the AFP gene was substantially reduced in Zhx2-expressing animals. To verify
differences in unspliced RNA levels between mice with or without Zhx2, PCR reactions
with primers targeting exon-intron or intron-intron boundaries were performed.
strategy will only detect unprocessed RNA.

This

In all the cases assessed (Figure 3-2,

middle and bottom panels of AFP E2-E3, AFP E5-E6, AFP E10-E11, AFP E12-E13, AFP
E14-E15), bands corresponding to the unspliced RNA showed higher intensity in the
presence of Zhx2 than in the absence of Zhx2. This strategy allowed detection of PCR
product due to unprocessed RNA in E2-E3 and E5-E6 and indicated that AFP splicing
repression mediated by Zhx2 is extended towards the 5’-end. Therefore, we conclude
that Zhx2 has a general effect on the splicing efficiency throughout the AFP gene which
would explain the reduced accumulation of AFP mRNA in adult BALB/cJ mice.

Analysis of cellular RNA fractions
Preliminary data demonstrated that Zhx2 was enriched in the chromatinassociated (insoluble) fraction, which is consistent with the idea that Zhx2 may be
involved in a co-transcriptional regulation step.

Therefore, the unprocessed RNA

observed in the presence of Zhx2 may be more abundant in the nuclear fraction. To
explore the cellular localization of the unspliced RNA, liver tissue from littermate mice
with or without the Flag-tagged Zhx2 transgene was fractionated into cytoplasmic,
chromatin soluble (NSol) and chromatin-associated (insoluble, NIns) fractions (PandyaJones and Black, 2009). RNA was extracted from each fraction, cDNA was made with
random hexamers and AFP expression was analyzed by PCR using primers spanning
AFP E10-E11 (Figure 3-3). β-actin and rpL30 were utilized as loading controls. U6
RNA, which is found exclusively in the nucleus, was used as a fractionation control. A
U6 RNA PCR product was observed only in the nuclear soluble and nuclear insoluble
fractions as expected, indicating that cytoplasmic fraction was clean. A PCR signal was
not detected in the nuclear insoluble fraction using primers targeting the AFP E10-E11 or
L30, suggesting that the spliced RNAs must be rapidly released from the chromatin and
unspliced AFP RNA is not retained in this fraction. However, PCR products from the βactin and U6 reactions were visible, indicating that the RNA in this fraction was not
degraded and thus, the absence of AFP E10-E11 PCR product was due to low
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abundance of the AFP transcript in this fraction. In the nuclear soluble fraction, both
spliced and unspliced AFP E10-E11 was detected and relatively more of the PCR band
corresponding to the spliced RNA was seen in absence of Zhx2.

Thus, the Zhx2

regulation of mature mRNA abundance is seen in the nucleus, consistent with this being
due to a nuclear regulatory event. However, there wasn’t an obvious difference in the
unspliced PCR product in the presence or absence of Zhx2. Surprisingly, a dramatic
difference was observed in the cytoplasmic fraction in which high accumulation of the
unspliced RNA was observed in presence of Zhx2 with concomitant lower levels of
spliced RNA, compared to that observed in absence of Zhx2. Negative controls without
RT enzyme were performed and no signal corresponding to PCR products for L30, βactin or AFP E10-E11 were observed, indicating there was no DNA contamination (data
not shown). This experiment was repeated with the cytoplasmic RNA fraction from other
independent sets of littermate mice and the same result was observed. Additional RTPCR reactions were performed with primer pairs spanning different exon-exon and exonintron boundaries (as shown in Figure 3-1) using the cytoplasmic RNA fractions (results
not shown). In all cases, higher levels of unspliced product was observed in presence of
Zhx2, indicating that unprocessed AFP transcripts are present in the cytoplasm and thus
have escaped from nuclear surveillance processes.
The cytoplasmic fraction was further characterized by analyzing poly-A+ and polyA- RNA fractions by RT-PCR.

A+ and A- RNA fractions were obtained from liver

cytoplasmic RNAs by separation through oligo-dT columns. cDNA was made from each
fraction utilizing random hexamers and PCR reactions were performed with primers
targeting AFP E10-E11, E14-E15 and L30 as an internal control (Figure 3-4). In the A+
fraction, the AFP E10-E11 spliced PCR product was mainly detected in absence of
Zhx2, consistent with the known mRNA expression differences seen in the presence or
absence of Zhx2. The unspliced product was not detected in either of the A+ RNA
fractions, indicating that the unspliced RNA is not polyadenylated. Indeed, the main
PCR product observed in the A- fraction corresponded to the unspliced RNA, which was
more abundant in presence of Zhx2. Similar results in both the A+ and A- fractions were
seen with the AFP E14-E15 primers. Although it was unexpected to find unspliced RNA
in the cytoplasmic fraction, there are some reports in the literature that unspliced RNAs
are found in the cytoplasm when splicing is inhibited with small molecules or mutations
in the core splicing machinery (Kaida et al., 2007; Legrain and Rosbash, 1989; O'Brien
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et al., 2008). Therefore, the data discussed here is consistent with global repression of
AFP splicing mediated by Zhx2.

Splicing analysis of other known targets of Zhx2
Other known targets of Zhx2 are the H19 and Gpc3 genes. We proceeded to
investigate whether Zhx2 may regulate expression of these genes by repressing premRNA splicing as was observed with AFP. Conventional RT-PCR was used to analyze
Gpc3 splicing in the presence and absence of Zhx2. Both cytoplasmic and nuclear
soluble fractions were used for cDNA preparation. PCR reactions were performed with
pairs of primers targeting exon and intron boundaries across the Gpc3 gene (Figure 35). Higher accumulation of spliced Gpc3 mRNA (PCR E4-E6 and PCR E7-E8) was
observed in absence of Zhx2 in both cytoplasmic and nuclear soluble fractions, though
the difference in abundance was not as obvious as that observed in the AFP gene as
seen previously (Morford et al., 2007). Unspliced product (Gpc3 I5-E6) was not detected
in the cytoplasmic fraction and little difference in accumulation was seen in the nuclear
soluble fraction.

PCR product signals for the unprocessed RNA were significantly

weaker than those observed for the spliced RNA, indicating that unprocessed transcripts
are present in lower abundance. To examine H19 splicing, primers in Exons 4 and 5
were used (Figure 3-5). No unspliced RNA was detected, but again, the repression due
to Zhx2 was seen in both the cytoplasmic and nuclear fractions. The fact that the Zhx2
regulation was seen in the nuclear RNA fraction is consistent with this being due to a
nuclear regulatory event, but it is not clear whether splicing is the regulated event for the
Gpc3 and H19 genes.
Preliminary data had indicated that unspliced H19 RNA could not be detected by
conventional RT-PCR.

Therefore, PCR amplification was performed using a 5’-end

radiolabeled primer to increase sensitivity. Splicing analysis across the H19 gene was
performed by using pairs of primers that target different exons of the H19 gene,
diagrammed in Figure 3-6A.

The cytoplasmic RNA fraction was used for cDNA

preparation because this fraction showed the higher difference in unprocessed AFP
RNA. In all the cases, higher accumulation of mRNA was observed in the absence of
Zhx2, which is consistent with previous Northern blot data (Figure 3-6B). However,
unspliced H19 RNA could not be detected by this procedure; genomic DNA was used as
a control to identify the correct size of unspliced RNA.

There are several possible

explanations for this outcome. One possibility is that splicing of H19 transcripts may be
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repressed but the unprocessed RNAs are rapidly turned over before they can reach the
cytoplasm. In fact, unspliced RNAs are usually rapidly degraded in the nucleus, so this
result with the H19 RNA may be expected. To detect splicing repression, it may be
better to examine nuclear RNA fractions. On the other hand, the H19 gene is small,
about 3.6 kb, compared to the AFP gene that is 20 kb, and consists of five exons
separated by unusually short introns (~79-87 bp) which may favor efficient splicing.
Thus, it is also possible that H19 is post-transcriptionally regulated at a step later than
splicing repression

Are introns required for Zhx2 regulation of target genes?
As discussed previously, the transcriptional rate across the AFP and H19 genes
are similar in spite of Zhx2 expression. However, in the presence of Zhx2 there is a
decrease of mRNA levels compared to that observed in absence of Zhx2.

This

difference in accumulated mRNA can be explained by general splicing inhibition of AFP
pre-mRNA mediated by Zhx2. Early transgenic mouse studies utilized the AFP promoter
to drive expression of AFP minigenes or the MHC class I H-2Dd (250AFP-Dd) gene, both
containing introns. These transgenes were developmentally repressed and regulated by
Zhx2 in a pattern similar to the endogenous AFP gene (Peyton et al., 2000a). However,
when Zhx2 was transiently co-transfected into liver cell lines with intron-less luciferase
reporter genes driven by the AFP promoter, only about a 2-fold repression was observed
(Shen et al., 2008).

It is possible that the lower fold repression observed with the

luciferase reporter gene is because introns may be required for or contribute to Zhx2
regulation. This hypothesis was tested using AFP minigenes that differ only by the
presence or absence of introns in littermate mice that either express the endogenous
Zhx2 gene or have the mutant BALB/cJ allele.

If introns are required for Zhx2

regulation, Zhx2 should regulate expression of the genomic AFP minigene whereas the
cDNA AFP minigene expression should not be regulated.
To test the prediction that introns are required for Zhx2 regulation, the AFP
minigenes diagrammed in Figure 3-7 were made, based on those used in previous
studies that are known to be repressed at birth and responsive to Zhx2 expression
(Peyton et al., 2000a; Vacher et al., 1992). These AFP mini-genes consist of the AFP
enhancer 2 and the 250 bp AFP promoter linked to AFP exon 1 through 3 fused to the
last two AFP exons (250AFP-MG), exon 14 and 15, either containing (genomic) or
lacking introns (cDNA). Additionally, an insertion of 18 bp was included within exon 15
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to allow exclusive detection of the AFP transgene. The AFP minigenes were sequenced
and their expression was tested in HepG2 cells before being introduced into mice. Both
genomic and cDNA AFP minigenes, were expressed at similar levels in HepG2 cells (A.
Ribble, data not shown). The AFP transgenes were introduced into mice expressing the
wild-type Zhx2 allele.

Only one founder from each line was obtained and each

backcrossed twice with BALB/cJ mice to determine whether these transgenes were
responsive to Zhx2 regulation. Total RNA from adult liver of littermate mice from each
line was analyzed by RT-PCR using primers targeting exon 3 and the 18-bp sequence
inserted within exon 15 (Figure 3-7).

Endogenous AFP and H19 RNA levels were

analyzed by RT-PCR as controls for Zhx2 responsiveness and L30 was used as an
expression control. In both the cDNA and genomic AFP minigene transgenic lines,
lower levels of endogenous AFP and H19 mRNA were observed in transgenic mice
expressing Zhx2 wild-type allele (Zhx2+), as was unspliced AFP RNA.

In contrast,

higher levels of endogenous AFP and H19 mRNA were observed in absence of Zhx2
expression, indicating that the endogenous Zhx2 targets genes were regulated in both
mouse lines, as expected.
Analysis of RNA from five transgenic littermate mice expressing the AFP cDNA
minigene showed that this transgene was responsive to Zhx2 regulation; lower minigene
mRNA levels were detected in mice that expressed the Zhx2 wild-type allele (Figure 3-7,
left panel; Zhx2+) compared to mice with the BALB/cJ allele (Figure 3-7, left panel;
Zhx2-). The estimated fold-repression of the AFP cDNA transgene was about 3 to 4-fold
while the endogenous H19 and AFP genes were repressed about 15-23-fold and 10-30fold, respectively. This indicated that the cDNA AFP transgene was not repressed to the
same extent as the endogenous AFP and H19 genes. In contrast, analysis of the AFP
genomic transgene, showed that it was not well expressed among the littermate mice
tested (Figure 3-7, right panel) and therefore, it was difficult to assess whether this
transgene was regulated. There was high expression variability among littermates that
did not correlate with the presence or absence of Zhx2. Similar results were obtained
from analysis of two independent litters from this AFP genomic transgenic line (data not
shown). Thus, while the cDNA transgene does appear to respond to Zhx2, the response
is not as robust as the endogenous gene, which may suggest that introns are not
required for Zhx2 regulation, but that they may contribute to the regulatory mechanism.
However, since expression of the AFP genomic transgene is so low, we can not use it as
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a positive control for this experiment to know whether the mutated transgene response is
due to the lack of introns.
Because we only obtained one founder animal from each of the transgenes
containing the AFP250 bp promoter and because the genomic minigene did not express
well, additional mouse lines expressing the AFP cDNA or genomic minigene under
control of the 1 kb AFP promoter and AFP E2 were generated (1kb AFP-MG) to test the
contributions introns make to Zhx2 regulation. It was anticipated that the 1 kb promoter
may provide more robust transgene expression. Five founder mice were obtained from
each construct and named A-E for the cDNA minigene and G-K for the genomic
minigene (Figure 3-8). Founders were crossed to BALB/cJ mice and at least two F1
mice from each founder were backcrossed to BALB/cJ. F2 mice were obtained from all
founders except for the H and I of the AFP genomic minigene line that were sterile. RNA
from adult liver of F2 littermate mice from A (Figure 3-9), E (Figure 3-10) and G (Figure
3-11 and Figure 3-12) founders were analyzed by RT-PCR as described above. In all
cases, the endogenous AFP and H19 mRNA was regulated by Zhx2. However, there
was variability in expression of AFP transgenes among the lines. The A2 AFP cDNAminigene line did not express the transgene well, based on the very low AFP E3-E15*
PCR signal (Figure 3-9). The AFP promoter-regulated transgenes should be repressed
by four weeks after birth, so to see whether transgene expression in the A2 line might be
higher at three weeks rather than five weeks after birth, multiple litters were collected at
various ages. However, this did not improve detection of this transgene. In all the other
cases, E2 AFP cDNA minigene and G1 and G2 AFP genomic minigene, AFP E3-E15*
PCR signals were detected but unexpectedly, no significant differences in the transgene
expression was observed in spite of the Zhx2 expression levels. These results indicated
that the transgenes were not strongly regulated by Zhx2. Other strategies were utilized
to analyze the AFP transgene expression, such as Northern blot and S1 nuclease
(results not shown). No bands for AFP minigene were visualized in Northern blot from
total RNA. Previous studies utilized A+ RNA because AFP is expressed in low levels in
adult liver. In general, the AFP transgenes were not well-expressed because about 2.5fold more cDNA was required in the PCR reactions to get a signal intensity similar to the
endogenous AFP gene. Additionally, low intensity bands corresponding to the AFP
minigene could be detected by S1 nuclease protection assays but it required over 75 µg
of total RNA. Based on the published literature, we fully expected that the AFP genomic
minigenes would be regulated by Zhx2; it is not clear why this is not the case.
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Alternative splicing across the AFP gene
Based on results described above, we conclude that AFP splicing efficiency is
dramatically reduced in Zhx2-expressing mice. To determine whether the presence of
Zhx2 also caused any alternative splicing of the AFP RNA, we searched for alternatively
spliced RNAs by RT-PCR using primers that spanned across different AFP exons
(Figure 3-13A). Total RNA from two pairs of littermate mice with or without the FlagZhx2 transgene was analyzed. Under these conditions, AFP E1-E6 and AFP E5-E11
PCR yielded only the products expected for fully spliced AFP mRNA and these products
were more abundant in the absence of Zhx2.

The fully spliced mRNA also was

observed for the AFP E10-E15 PCR, but in this case a weak smaller band of about 430
bp was also observed. The E10-E15 region was further analyzed to determine whether
this band corresponded to an alternatively spliced AFP mRNA (Figure 3-13B). AFP
E10-E12, AFP E10-E13 and AFP E11-14 PCRs yielded PCR products with the expected
sizes for the fully spliced AFP mRNA. In addition, the AFP E10-E13 PCR also produced
PCR products with smaller sizes.

These other PCR products may be derived from

alternatively processed RNAs or they may be artifacts from the PCR amplification.
However, because the overlapping E10-E12 and E11-E14 PCR reactions did not detect
any smaller products, it is more likely that the products in E10-E13 are PCR artifacts.
Also, the abundance of these products was the same in the presence or absence of
Zhx2.

Thus, we did not pursue this further and conclude that there is no obvious

alternative splicing mediated by Zhx2.

Nuclear extract preparation from mouse liver and Flag-tagged Zhx2 Immunoprecipitation
As discussed previously, Zhx2 regulates AFP expression post-transcriptionally by
repressing AFP splicing in a promoter dependent manner. It is possible that Zhx2 may
interfere with factors that directly or indirectly affect the pre-initiation complex.
Alternatively, Zhx2 may affect steps of RNAPII elongation that impact posttranscriptional steps such as RNA splicing, RNA export and/or RNA degradation. To
gain more insight into the mechanism of Zhx2 regulation, we intend to identify proteins
that interact with Zhx2 using a proteomics approach.

This strategy requires co-

purification of Flag-tagged Zhx2 and its interacting proteins from liver nuclear extracts by
immunoprecipitation with anti-Flag M2 agarose beads, followed by mass spectrometry.
Transgenic mice that express Flag-tagged Zhx2 in the liver will be used in these
experiments.

Analysis of liver tissue fractions from Flag-Zhx2 transgenic mice by
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Western blot demonstrated that the Flag-Zhx2 protein appeared mainly in the chromatinassociated fraction with the hyperphosphorylated RNAPII (Morford, L., unpublished
data).

It was also shown that Flag-Zhx2 was expressed at similar levels to the

endogenous liver Zhx2 in wild-type mice and thus, similar to physiological levels.
Moreover, Flag-Zhx2 expression in transgenic mice also complemented the Afr1
phenotype, so the AFP and H19 mRNAs were repressed after birth to the same extent
as observed in mice that express wild-type Zhx2. Therefore, livers of these transgenic
mice are ideal starting material for achieving the co-purification of Flag-Zhx2 and in vivo
partners for the proteomic study.
Because Zhx2 was found to be tightly associated with the chromatin-insoluble
fraction, the first step was to find a nuclear extract (NE) protocol that allowed recovery of
Flag-Zhx2 without disrupting protein-protein interactions.

As a control for unspecific

interactions, littermate mice that did not express the Flag-Zhx2 transgene were included.
NE were prepared by lysis of purified nuclei obtained from liver of adult mice with or
without the Flag-Zhx2 transgene.

Lysis of nuclei were performed based on three

different protocols (Aygun et al., 2008; Dignam et al., 1983; Wuarin and Schibler, 1994)
and analyzed by Western blot with anti-Flag or anti-Zhx2 antibodies. The best results
were obtained using a Dignam-based protocol (Ausubel et al., 1987). NE preparation
was optimized using buffers with different concentration of NaCl and KCl. The best
Flag-Zhx2 recovery was obtained with 300 mM to 400 mM KCl (results not shown).
Preparation of NE using this methodology was reproducible and at least half of the FlagZhx2 protein was recovered from the chromatin-insoluble pellet. Figure 4-14A shows a
representative Western blot with anti-Zhx2 antibody for one NE preparation using 400
mM KCl in lysis buffer. As a positive control, NE from transfected HEK-293 cells with a
plasmid expressing the Flag-tagged Zhx2 was prepared; Western blot analysis with antiZhx2 detects a band of about 98 KDa, which is the expected size for the Flag-Zhx2
protein product (Figure 3-14, Lanes 1 and 8). Similar results were observed with the
anti-Flag antibody (results not shown). Analysis by Western blot of the NE prepared
from the mice that expressed the Flag-Zhx2 transgene (NE+) also showed the 98 KDa
band recognized by the anti-Zhx2 antibody that is not observed in the NE from littermate
mice not expressing the transgene.

The next step was optimizing the Flag-Zhx2

immunoprecipitation using the anti-Flag agarose beads.

As an initial trial,

immunoprecipitation was performed following the procedure indicated in the instruction
manual. NE input and eluate from the immunoprecipitation were analyzed by Western
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blot as shown in Figure 3-14B. The band of 98 KDa is observed in the eluate from NE of
mice that expressed the Flag-Zhx2 (lanes 9 and 10, Figure 3-14B) that is not observed
in the eluate from NE of transgene-negative mice (lanes 11 and 12, Figure 3-14B),
indicating that this procedure could specifically pull down the Flag-tagged Zhx2 protein.
However, one concern was that the buffer used in this immunoprecipitation assay
contained 1% Triton X-100, which may be too harsh for maintaining some protein-protein
interactions and is known to interfere with mass spectrometry. Because NF-YA was
reported to interact with ZHX2 in HEK-293 cells (Kawata et al., 2003b), it could be used
as a positive control for protein co-immunoprecipitation. Other IP trials were performed
with reduced the detergent concentration, but a precipitate formed during the incubation
of the NE with the agarose beads, and the eluates showed no specificity.
DISCUSSION
The results presented here indicate that Zhx2 dramatically reduces splicing
efficiency of the AFP transcript. This is consistent with the reduced steady state AFP
mRNA levels and increased pre-mRNA accumulation observed in the presence of Zhx2.
Interestingly, the repression of splicing was observed across all the introns analyzed
indicating that the effect on splicing is global rather than being specific for certain introns.
Surprisingly, analysis of the cellular RNA fractions demonstrated that the higher
accumulation of fully unspliced RNA was observed in the cytoplasmic RNA fraction.
Moreover, analysis of the cytoplasmic A+ and A- RNA fractions showed that the
unspliced AFP RNA is mainly in the A- RNA fraction. This result suggested that the
unspliced AFP RNA found in the cytoplasm is not polyadenylated or that the poly-A tail is
too short to bind to the oligo-dT column.

Therefore, the unprocessed AFP RNA is

escaping the nuclear surveillance mechanisms and being exported to the cytoplasm
where it is likely deadenylated. Although these findings were unexpected, there are
some reports in the literature indicating that pre-mRNA could leak into the cytoplasm and
even be translated when splicing is repressed by small molecules or mutations that
target spliceosome components (Kaida et al., 2007; Legrain and Rosbash, 1989; Lo et
al., 2007; O'Brien et al., 2008). Thus, the presence of unspliced AFP transcripts in the
cytoplasm is consistent with the idea that Zhx2 globally represses splicing of AFP premRNA.
Zhx2 also decreased mRNA accumulation of other two target genes, H19 and
Gpc3, and at least H19 was shown by nuclear run-on to be transcribed at the same rate
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in the presence or absence of Zhx2. It may be expected that Zhx2 will affect expression
of these genes by a similar mechanism. Therefore, we investigated whether splicing of
these genes was repressed similarly to that observed for AFP gene. Radiolabeled RTPCR reactions were performed to detect unspliced H19 RNA in the cytoplasmic RNA
fraction to increase the sensitivity of the assay compared to standard RT-PCR. With
these assays, a lower accumulation of PCR product corresponding to the mRNA was
observed in the presence of Zhx2, but PCR products corresponding to unspliced RNA
were not detected across the multiple exon-exon regions of the H19 gene analyzed
(Figure 3-5). One possible explanation for this result is that Zhx2 inhibits H19 splicing
but unprocessed H19 RNA is rapidly turned over in the nucleus, as normally occurs with
aberrant spliced transcripts. Additional experiments should be done analyzing nuclear
RNA and primers that target exon-intron or intron-intron regions as another way to
determine whether there are differences in accumulation of unspliced H19 RNA in the
presence of Zhx2. In the case of Gpc3, there was a lower accumulation of spliced RNA
in presence of Zhx2 in both nuclear and cytoplasmic RNA fractions, but the difference
was not as marked as that observed in the H19 and AFP genes. Unspliced Gpc3 RNA
product was not detected in the cytoplasmic fraction and no remarkable difference was
observed in the nuclear soluble fraction between the presence or absence of Zhx2. The
fact that Gpc3 pre-mRNA is not detected in the cytoplasm suggested that any unspliced
Gpc3 transcripts must be rapidly processed or degraded.

Together, these splicing

results raise the question of what accounts for the unexpected stability of unprocessed
AFP RNA compared to the transcripts of other Zhx2 target genes? In fact, it is perhaps
fortunate that unprocessed AFP RNA is stabilized so that it can be detected as it
provides important clues to the Zhx2 regulatory mechanism. It is not clear at this point
whether Zhx2 affects splicing of target genes in the same way as the AFP gene or
whether other post-transcriptional mechanism may be involved. Further analysis of the
nascent RNA splicing, in chromatin-associated RNA fractions, may provide information
about Zhx2 regulation of the H19 and Gpc3 genes.
Analysis of AFP intron requirement for Zhx2 regulation in transgenic mice
Because Zhx2 affected the splicing of AFP pre-mRNA, whether AFP introns were
required for Zhx2 mediated regulation also was investigated.

For this purpose

transgenic mice that expressed AFP minigenes in its cDNA or genomic (intron
containing) forms were generated. These minigenes were based on other constructs
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that were reported to be repressed after birth and responsive to Zhx2. The cDNA AFP
minigene driven by 250 bp AFP promoter was regulated in response to Zhx2 but the
fold-change between mice that did or did not express Zhx2 was smaller than the
difference in the endogenous AFP and H19 genes.

However, the genomic AFP

minigene driven by the 250 bp AFP promoter was not expressed well in the transgenic
mice and therefore, its regulation by Zhx2 could not be assessed. Transgenic mice that
expressed the cDNA or the genomic AFP minigenes driven by the 1 kb AFP
repressor/promoter region were also generated.

Surprisingly, these AFP minigenes

were not strongly regulated in response to Zhx2 in the F2 offspring from E (cDNA) and G
(genomic) founders, while the cDNA AFP minigene was not expressed well in the F2
offspring from the A founder.

In contrast, endogenous AFP and H19 genes were

regulated by Zhx2 as expected in all the cases.

No obvious Zhx2 regulation was

observed either by S1 analysis or by semi-quantitative RT-PCR analysis. F2 littermate
liver RNA from three other cDNA transgene founders and two other genomic AFP
transgene founders remain to be analyzed. At this point, why these minigenes are not
regulated in response to Zhx2 is not known.
Mechanism of AFP splicing repression by Zhx2
Transport of pre-mRNA to the cytoplasm has been observed by interfering with
early steps in the spliceosome assembly. This includes mutations in U1 snRNA or
mutations in either the 5’ splice site or the branchpoint sequence (Legrain and Rosbash,
1989).

Accumulation of pre-mRNAs in the cytoplasm also was induced with

spliceostatin A, an inhibitor of splicing, which target the SF3b subcomplex of the U2
snRNP (Kaida et al., 2007). Because SF3b interacts with components of the retention
and splicing (RES) complex in yeast, it was suggested that SF3b is involved in
recognizing intron-containing transcripts for nuclear retention. Based on these studies it
can be proposed that Zhx2 might interfere with recruitment of one or more of the transacting factors involved in early spliceosome assembly and subsequently, avoid the
nuclear retention and degradation. If this is the mechanism by which Zhx2 regulates its
target genes, it would require introns for regulation. Because preliminary results suggest
that a cDNA transgene is at least partially regulated, it is possible that introns contribute
to the Zhx2 regulation but they can not be required.
Only a few other cases of gene regulation by intron retention have been
observed, one being in the posttranscriptional regulation of the TNF gene expression
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(Yang et al., 1998). TNF pre-mRNA was found to accumulate in the nucleus in naïve T
cells. Upon T cell activation, TNF pre-mRNA splicing was quickly induced, resulting in
high levels of TNF mRNA and protein.

The mechanism by which TNF pre-mRNA

splicing is repressed in naïve T cells and then induced soon after T cell activation,
remains unknown. However, it was suggested that a negative regulator may block TNF
pre-mRNA processing and be released upon T cell activation to allow proper TNF premRNA processing. Another example of regulation through intron retention is observed
in the primary response genes (PRGs), which produce full-length transcripts, but no
mRNA, in unstimulated macrophage (Hargreaves, 2009). Promoters of PRGs are preassociated with serine 5-phosphorylated RNAPII prior LPS stimulation, allowing
transcription of full-length pre-mRNA that are quickly degraded rather than spliced.
Uninduced promoters do not recruit pTEF-b to phosphorylate RNAPII on serine 2, which
is required for co-transcriptional RNA processing, because the promoters are bound by
co-repressor molecules. Upon LPS stimulation, pTEF-b is recruited through the adaptor
protein Brd4, inducing RNAPII phosphorylation at serine 2 and generation of mature
RNA.
By analogy to these situations, it is possible that Zhx2 interferes with recruitment
of factors involved in coupling transcription with RNA processing factors (Figure 3-15),
for example by blocking RNAPII phosphorylation. This would result in AFP pre-mRNA
splicing inhibition and concomitant reduction of AFP mRNA. These factors may also
impact stability of the AFP pre-mRNA and avoid nuclear retention. Therefore, AFP premRNA could escape from the nuclear surveillance mechanisms and be transported to
the cytoplasm. Insight into the mechanism of Zhx2 regulation could be obtained by
proteomic analysis of Zhx2-interacting proteins.
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Figure 3-1. Scheme of PCR reactions performed for analysis of AFP splicing.
Diagram of the 15-exon AFP structural gene and location of the PCR primer pairs
utilized for AFP splicing analysis. B1 is a repetitive element within intron 1 known to be
transcribed by RNA polymerase III from the opposite strand to that encoding AFP RNA
(Godbout et al., 1986). AFP E2-E3, primers E2E3-F/E2E3-R; AFP I1-I2, primers i1-F/i2R; AFP E2-I2, primers E2E3-F /i2-R; AFP I2-I3, primers i2-F/i3-R; AFP E5-E6, primers
E5-F/E5E6-R; AFP E5-I5, primers E5-F/i5-R; AFP E14-E15, primers Afp3’-F/Afp3’-R1;
AFP E14-pA, primers Afp3’-F/Afp3’-R2; AFP I9-I10, primers i9-F/i10-R; AFP I10-I11,
primers i10-F/ i11-R; AFP E10-E11, primers E10E11-F/ E10E11-R, AFP E12-E13,
primers E12E13-FB/E12E13-RB, AFP I12-I12, primers nest12-13BF/nest12-13BR. All
primer sequences are listed in Table 2-3.
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Figure 3-2. AFP pre-mRNA splicing is repressed in the presence of Zhx2. RT-PCR
reactions using total RNA extracted from adult liver of two independent sets of littermate
mice with (Zhx2+) or without (Zhx2-) the Flag-Zhx2 transgene. cDNA was made from 1
µg of total RNA and PCR reactions were performed with 1 to 5 µl of cDNA diluted 1:5.
The expected sizes of the PCR products are shown on the left; a diagram of the location
of each primer pair is shown on the right. PCR products were collected at different
cycles to ensure a linear PCR amplification range (only one set of reactions is shown).
rpL30 is used as loading control (23 cycles); AFP E2-E3, AFP I1-I2, AFP E2-I2, AFP I2I3, AFP E5-E6, AFP E5-I5, AFP E14-E15, AFP E14-pA (33 cycles); AFP I9-I10, AFP
I10-I11 (30 cycles); AFP E10-E11, AFP E12-E13, AFP I12-I12 (31 cycles). To check for
DNA contamination, negative controls without RT enzyme were performed followed by
PCR amplification with primers for L30 and AFP E10-E11 as described above.
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Figure 3-3. Splicing analysis of AFP transcripts in cellular RNA fractions from
liver of littermate mice with or without the Flag-Zhx2 transgene. cDNA was made
from 1 µg of the indicated RNA fraction. PCR reactions were performed with 1 to 5 µl of
cDNA diluted 1:5 from cytoplasmic RNA fraction and undiluted cDNA from nuclear
soluble or insoluble RNA fractions. PCR products were collected at different cycles to
ensure a linear PCR amplification range (only one set of reactions is shown). rpL30
(L30R/L30F2) was used as loading control (27 cycles); AFP E10/E11 PCR (E10E11-F/
E10E11-R; 31 cycles), β actin PCR (B-ActF/ B-ActR; 26 cycles cytoplasmic fraction and
29 cycles nuclear soluble and insoluble fractions), U6 PCR (U6F/U6R; 26 cycles). U6
PCRs were performed from cDNAs prepared with 1 µg of RNA fractions without dilution,
so that undetectable levels of U6 in the cytoplasmic fractions was not due to a dilution
factor. U6 PCR for nuclear soluble fractions were performed under same conditions but
at 27 cycles. The AFP and β actin lanes shown were assembled from non-adjacent
lanes of the same gel.
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Figure 3-4. Splicing analysis of cytoplasmic A+ and A- RNA fractions. Liver
cytoplasmic RNA from littermate mice with or without the Flag-Zhx2 transgene were
fractionated into A+ and A- RNA fractions using oligo-dT columns. cDNA was made
using 1 µg of A- RNA fraction or 12 ng of A+ RNA fraction with random hexamers. PCR
reactions were performed with 0.5 µl of cDNA for L30 PCR or 2 µl of cDNA for AFP
E10/E11 PCR. PCR products were collected at different cycles to ensure a linear PCR
amplification range (only one set of reactions is shown). rpL30 (primers L30R/L30F2)
were used as loading control (23 cycles); AFP E10/E11 PCR, primers E10E11-F/
E10E11-R (31 cycles); AFP E14/E15 PCR, primers E14E15-F/Afp3’-R1 (33 cycles). All
primer sequences are listed in Table 2-3.
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Figure 3-5. Splicing analysis of Gpc3 RNA in cytoplasmic and nuclear soluble RNA
liver fractions. RNA was extracted from cytoplasmic and nuclear soluble fractions of
liver tissue obtained from littermate mice with or without the Flag-Zhx2 transgene. cDNA
was made with 1 µg of the indicated RNA fractions. PCR reactions performed with 1-2
µl of cDNA diluted 1:5 from the cytoplasmic RNA fraction and cDNA undiluted from the
nuclear soluble fractions. PCR products were collected at different cycles to ensure a
linear PCR amplification range. rpL30 (L30R/L30F2) was used as loading control (22
cycles); Gpc3 E4/E6 PCR (Gpc3URT/Gpc3LRT, 33 cycles); Gpc3 I5/E6 (Gpc3 U2/Gpc3LRT, 32 cycles); Gpc3 E7/E8 PCR (Gpc3E7-U/Gpc3E8-L, 33 cycles); H19 PCR
Exons 4 and 5 (S-H19/AS-H19, 30 cycles).
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Figure 3-6. Splicing analysis of H19 RNA in cytoplasmic RNA liver fractions. 1 µg
of cytoplasmic RNA fractions from littermate mice with or without the Flag-Zhx2
transgene were used for cDNA preparation with random hexamers. PCR amplification
was performed with 5 µl of cDNA diluted 1:5 and primers targeting different exon-exon
regions of H19 gene represented in (A). All PCR reactions were carried out for 29
cycles at 55 ºC with the reverse primer radiolabeled with polynucleotide kinase (PNK)
and [γ-32P]-ATP. PCR products were analyzed on 6% or 8% denaturing polyacrylamide
gels and detected by phosphorimaging (B). Boxes indicated PCR products
corresponding to spliced mRNA. “*” indicates the PCR product from genomic DNA used
as positive control (C) for expected size of the unspliced RNA. From left to right: PCR
E1-E2, primers E1E5H19-F/ H19Ex2-L; PCR E1-E3, primers E1E5H19-F/H19Ex3-L3;
PCR E2-E3, primers H19Ex2-U/H19Ex3-L2; PCR E2-E3, primers H19Ex2-U/H19Ex3L3; PCR E2-E5, primers H19Ex2-U/E1E5H19-R.
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Figure 3-7. Splicing regulation by Zhx2 of AFP minigenes driven by the 250 bp
AFP promoter region. (A) AFP minigenes used in previous studies contained the
albumin enhancer and 1kb promoter to drive expression of a short version of the AFP
gene where the internal sequence from exon 4 through exon 13 was deleted (Vacher et
al., 1992). The second construct contains the AFP enhancer II and AFP 250 bp
promoter to drive expression of the class I MHC Dd gene (Peyton et al., 2000a). Both
construct were repressed after birth and responsive to Zhx2 regulation. Based on these
transgenes, the AFP minigenes in the genomic or cDNA forms were designed. These
AFP genomic and cDNA minigenes were driven by the AFP enhancer II and AFP 250 bp
promoter. Additionally, an 18 bp sequence was inserted within exon 15 (*) to detect the
transgene by RT-PCR. To study regulation of transgene by Zhx2, at least two offspring
from each founder were backcrossed to BALB/cJ. RNA was extracted from livers of 3-4
week old F2 littermate mice and analyzed by RT-PCR (B). cDNA was prepared from 1
µg of RNA and 1-2 µl of 1:5 diluted cDNA was used for PCR amplification. AFP
transgene, AFP E3-E15 PCR, primers E3F/E15R (2 µL RT 1:5 diluted, 33 cycles);
endogenous AFP and H19 expression was analyzed as control for Zhx2 regulation: AFP
E10-E11 PCR, primers E10E11-F/ E10E11-R (2 µL RT 1:5 diluted, 31 cycles). H19
PCR, primers S-H19/AS-H19 (1 µL RT 1:5 diluted, 28 cycles cDNA transgene and 29
cycles genomic transgene samples). rpL30 was used as loading control, primers
L30R/L30F2 (1 µL RT 1:5 diluted, 23 cycles cDNA transgene and 22 cycles genomic
transgene samples).
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Figure 3-8. Scheme of transgenic founder mice expressing the cDNA and genomic
AFP minigenes driven by the 1kb AFP promoter region. (A) AFP cDNA and genomic
minigene as described in figure 4-7 (A) but driven by the AFP enhancer II and AFP 1kb
promoter. (B) Founders expressing the AFP cDNA (A-E) and genomic (G-K) minigenes.
Founder animals were crossed to BALB/cJ mice. To study regulation of the transgene
by Zhx2, at least two offspring from each founder were backcrossed to BALB/cJ. The
numbers indicate the number of litters harvested for RNA analysis. The H and I
founders were sterile and K1 did not segregated the transgene; these are indicated by
an “X”. Not all of the litters have been analyzed yet.
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Figure 3-9. Analysis of splicing regulation by Zhx2 of the AFP cDNA minigene
driven by the 1kb AFP promoter region, line A2. 1 µg of liver RNA from 3-5 week old
littermate mice was used for cDNA preparation and 1-5 µl of 1:5 diluted cDNA was used
for PCR amplification. AFP transgene expression was determined by AFP E3-E15 PCR
(primers E3F/E15R, 5 µL RT 1:5 dilution and 33 cycles) or AFP E14-E15 (primers
E14E15-F/E15R, 5 µL RT 1:5 dilution and 31 cycles); endogenous AFP and H19
expression was analyzed as controls for Zhx2 regulation by primer targeting the AFP
E10-E11 (E10E11-F/E10E11-R, 2 µL RT 1:5 dilution and 31 cycles) and the H19 gene
(S-H19/AS-H19, 2 µL RT 1:5 dilution and 30 cycles). Zhx2 expression levels were
determined with primers Z2HD1-F/ Z2HD1-R (3 µL RT 1:5 dilution and 30 cycles). rpL30
(L30R/L30F2, 1 µL RT 1:5 dilution and 25 cycles) was used as loading control. The
numbers below the figure are the sample tracking numbers of the animals analyzed.
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Figure 3-10. Analysis of splicing regulation by Zhx2 of AFP cDNA minigene driven
by the 1kb AFP promoter region, line E2. 1 µg of liver RNA from 5 weeks littermate
mice was used for cDNA preparation and 1-5 µl of 1:5 diluted cDNA was used for PCR
amplification. AFP transgene expression was determined by AFP E3-E15 PCR (primers
E3F/E15R, 5 µL RT 1:5 dilution and 31 cycles) or AFP E14-E15 (primers E14E15F/E15R, 5 µL RT 1:5 dilution and 31 cycles); endogenous AFP and H19 expression was
analyzed as controls for Zhx2 regulation by primers targeting AFP E10-E11 (E10E11F/E10E11-R, 2 µL RT 1:5 dilution and 31 cycles) and the H19 gene (S-H19/AS-H19, 2
µL RT 1:5 dilution and 30 cycles). rpL30 (L30R/L30F2, 1 µL RT 1:5 dilution and 25
cycles) was used as loading control. The numbers below the figure are the sample
tracking numbers of the animals analyzed.
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Figure 3-11. Analysis of splicing regulation by Zhx2 of AFP genomic minigene
driven by the 1kb AFP promoter region, line G1. 1 µg of liver RNA from 3 or 5 week
old littermate mice was used for cDNA preparation and 1-5 µl of 1:5 diluted cDNA was
used for PCR amplification. AFP transgene expression was determined by AFP E3-E15
PCR (primers E3F/E15R, 5 µL RT 1:5 dilution, 30 cycles samples 127-130 and 31 cycles
samples 46-51) or AFP E14-E15 (primers E14E15-F/E15R, 5 µL RT 1:5 dilution, 31
cycles); 490 bp band in AFP E3-E15 PCR correspond to the expected size of RNA
transcripts with intron 14 retention. Endogenous AFP and H19 expression was analyzed
as controls for Zhx2 regulation by primers targeting AFP E10-E11 (E10E11-F/E10E11-R,
2 µL RT 1:5 dilution, 31 cycles) and the H19 gene (S-H19/AS-H19, 2 µL RT 1:5 dilution,
30 cycles). Zhx2 expression levels were determined with primers Z2HD1-F/ Z2HD1-R (3
µL RT 1:5 dilution, 31 cycles samples 127-130 and 33 cycles samples 46-51). rpL30
(L30R/L30F2, 1 µL RT 1:5 dilution, 25 cycles) was used as loading control. The numbers
below the figure are the sample tracking numbers of the animals analyzed.
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Figure 3-12. Analysis of splicing regulation by Zhx2 of AFP genomic minigene
driven by the 1kb AFP promoter region, line G2. 1 µg of liver RNA from 3 or 5 week
old littermate mice was used for cDNA preparation and 1-5 µl of 1:5 diluted cDNA was
used for PCR amplification. AFP transgene expression was determined by AFP E3-E15
PCR (primers E3F/E15R, 5 µL RT 1:5 dilution, 30 cycles) or AFP E14-E15 (primers
E14E15-F/E15R, 5 µL RT 1:5 dilution, 31 cycles); endogenous AFP and H19 expression
was analyzed as controls for Zhx2 regulation by primers targeting AFP E10-E11
(E10E11-F/E10E11-R, 2 µL RT 1:5 dilution, 31 cycles) and the H19 gene (S-H19/ASH19, 2 µL RT 1:5 dilution, 30 cycles). Zhx2 expression levels were determined with
primers Z2HD1-F/ Z2HD1-R (3 µL RT 1:5 dilution, 31 cycles). rpL30 (L30R/L30F2, 1 µL
RT 1:5 dilution, 25 cycles) was used as loading control. The numbers below the figure
are the sample tracking numbers of the animals analyzed.
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Figure 3-13. Analysis of alternative splicing across the AFP gene. cDNA was
made from 1 µg of total RNA from liver of two sets of littermate mice with or without the
Flag-Zhx2 transgene. (A) One to five µl of 1:5 diluted cDNA was used for PCR
amplification of the AFP gene regions indicated on the left. The expected sizes of the
PCR products corresponding to the fully spliced mRNAs are shown on the left. To further
examine the ~430 bp product in the AFP E10-E15 reaction, the additional PCR reactions
in (B) were performed. On the right are shown the predicted PCR product sizes for
alternatively spliced RNAs if specific exons are skipped (identified by Δ). rpL30 (primers
L30R/L30F2) was used as a loading control and is shown in Figure 4-2. PCR E1-E6,
primers E1F and E5E6R; PCR E5-E11, primers E5-F and E10E11-R; PCR E10-E15,
primers E10E11-F and E13E15-R; PCR E10-E12, primers E10E11-F and AFPE12A;
PCR E10-E13, primers E10E11-F and E12E13-RB; PCR E11-E14, primers E14R and
E11E12F.
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Figure 3-14. Nuclear extract preparation from liver of Flag-Zhx2 transgenic mice
and anti-Flag-epitope immunoprecipitation. (A) Total nuclei (lanes 2 and 5, 10 µl),
nuclear extract (lanes 3 and 6, 20 µl) and the insoluble pellet (lanes 4 and 7, 20 µl)
fractions from liver of mice with (+) or without (-) the Flag-Zhx2 transgene were analyzed
by Western blot with a rabbit polyclonal anti-Zhx2 antibody. (B) 100 µg of nuclear
extracts from an independent preparation to that shown in (A) was used for
immunoprecipitation using the M2 anti-flag agarose (Sigma). NE input (lanes 9 and 11,
50 µg) and respective eluates (lanes 10, and 12). NE from transiently transfected
HEK293 cells were used as positive control and molecular size reference for Flag-Zhx2
(lanes 1 and 8, 2.5 µg total protein per line).
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Figure 3-15. Proposed model for Zhx2-mediated splicing repression of AFP gene.
(A) Before birth levels of Zhx2 are low consistent with high expression of AFP during
fetal development. In the absence of Zhx2 expression, AFP RNA transcripts are fully
spliced resulting in high levels of mRNA accumulation and AFP protein expression. (B)
After birth levels of Zhx2 increase and AFP expression is repressed. Our data suggest
that Zhx2 interferes with normal splicing so that AFP mRNA levels are low. Possible
mechanisms include blocking recruitment of splicing factors or altering RNA polymerase
II phosphorylation. Zhx2 may also be acting indirectly.
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CHAPTER IV
TRANSCRIPTION TERMINATION IN THE Cµ GENE

INTRODUCTION
Termination of RNAPII transcription occurs at variable distances downstream
from functional cleavage-polyadenylation [poly(A)] signals to recycle RNAPII complexes
and prevent read-through transcription into adjoining genes. Termination has also been
shown to enhance protein and mRNA expression from genes transiently transfected into
cells (West and Proudfoot, 2009). While a functional poly(A) signal is essential for
termination, additional sequences downstream from poly(A) signals are also required in
some genes (Richard and Manley, 2009). For example, RNAPII pause sites have been
identified downstream of multiple poly(A) signals (Ashfield et al., 1991; Enriquez-Harris
et al., 1991; Gromak et al., 2006; Peterson et al., 2002). Also, an element positioned
between 800 and 1600 nt downstream from the human β-globin poly(A) signal, which
was shown to have co-transcriptional cleavage (CoTC) activity, is required for β-globin
gene termination (Dye and Proudfoot, 2001).

This CoTC cleavage element also

functions to direct transcription termination when it is moved to a position about 200 nt
from the poly(A) signal (Dye and Proudfoot, 2001). The β-globin CoTC element can also
be replaced by the well-characterized MAZ4 RNAPII pause element or a pause element
found downstream from the human β-actin gene (Gromak et al., 2006). The human εglobin gene and the mouse serum albumin gene were also found to have a termination
region that contained CoTC activity (Dye and Proudfoot, 2001; West et al., 2006), but
CoTC activity is not found in all terminator regions examined (Gromak et al., 2006; Plant
et al., 2005).
The current model for how RNAPII terminates downstream from protein-coding
genes is a hybrid version of two original models (Bentley, 2002). Transcription through a
poly(A) signal seems to make the RNAPII complex “termination competent”; a functional
poly(A) signal is always required. Once the nascent transcript is cleaved, either by the
cleavage-polyadenylation machinery acting on the poly(A) signal or by a CoTC element,
the exposed 5’ end of the 3’ product becomes an entry point for an exonuclease to
degrade the downstream RNA. This is required, but not sufficient, for RNAPII to release
the template DNA (West et al., 2008). RNAPII is often seen to pause downstream from
poly(A) signals, in some cases, it is due to the presence of specific sequences (Dye and
Proudfoot, 2001; Fong and Bentley, 2001; Peterson et al., 2002) and in others, the
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pausing is directed by the poly(A) signal itself (Orozco et al., 2002). While this model for
the events that occur after RNAPII transcribes a poly(A) signal provides a framework for
understanding the termination process, not all the details of this process have been
established. In addition, it is not yet clear how termination downstream of more complex
transcription units, such as genes containing multiple poly(A) signals, is regulated or
whether termination is a part of the regulatory choice among multiple poly(A) signals.
The immunoglobulin M (µ) gene is a complex transcription unit that contains two
poly(A) signals, µs and µm. The upstream µs poly(A) signal is within the Cµ4-M1 intron
and the relative strengths of the competing cleavage-polyadenylation and splicing
reactions is a major determinant of which mRNAs are produced. In B cells, the µs
poly(A) signal is recognized less efficiently so more spliced µm mRNA is made whereas
in plasma cells, use of the µs poly(A) signal predominates over Cµ4-M1 splicing,
resulting in mostly µs mRNA being produced. Transcription termination in the µ gene
has been well-studied and was shown to change during B lymphocyte development; the
transcription unit is gradually foreshortened as B cells mature to plasma cells (Kelley and
Perry, 1986; Peterson, 2007; Weiss et al., 1989; Yuan and Tucker, 1984). In B cells,
transcription terminates far downstream of the distal µm poly(A) signal while in plasma
cells, transcription terminates in the vicinity of this µm poly(A) signal, about 2 kb
downstream from the upstream µs poly(A) signal. It is possible that the developmental
differences in the extent of transcription may be due to changes in the use of the poly(A)
signals in this gene. A RNAPII pause element was identified in the region 50 – 200 nt
downstream of the µs poly(A) signal (Peterson et al., 2002). When this element was
deleted, the amount of RNA cleaved and polyadenylated at the µs poly(A) site
decreased while the RNA spliced between the Cµ4 and M1 exons was increased, in
both B cells and plasma cells.

Thus, this element contributes to the balance in

efficiencies between the competing splice and cleavage-polyadenylation reactions, but
does not seem to be directly involved in the RNA processing regulation. This pause
element can be replaced by pause elements found downstream of other poly(A) signals
(Peterson et al., 2002) and can cause RNAPII pausing in heterologous contexts
(Peterson et al., 2002; Robson-Dixon and Garcia-Blanco, 2004).

Whether any co-

transcriptional cleavage activity exists within the µ gene locus that may contribute to the
developmental termination has not been investigated.
Much of our knowledge of transcription termination and how CoTC and/or pause
elements are involved in this process have been established using a model substrate,
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where the human β-globin gene driven by the highly active HIV promoter was transiently
transfected into HeLa cells. While this model system has discovered mechanistic details
that would have been difficult to find in less robustly expressed genes, it is an artificial
system, which raises the question of how broadly the details apply to natural
transcription units. Thus, to examine the effects of the CoTC element in another context
and determine how it affects transcription termination and alternative RNA processing
choices of a more complex transcription unit, we have introduced the CoTC element into
the well-studied mouse µ gene and explored the effects in stably transfected lymphocyte
cell lines. While the β-globin CoTC element has been shown to promote termination
downstream from poly(A) signals, it did not disrupt splicing when placed within the 850 nt
β globin second intron (Dye et al., 2006). However, placement of the β-globin CoTC
element in the 1862 nt Cµ4-M1 intron may have several possible outcomes. It was
possible that splicing of the longer Cµ4-M1 intron would be disrupted, depending on how
fast cleavage occurs, relative to transcription of the complete intron. On the other hand,
CoTC elements and pause sites were functionally interchangeable downstream from the
β globin poly(A) signal (Gromak et al., 2006). Therefore, it was possible that the CoTC
element would be able to replace the activity of the µ pause element, or since pause and
CoTC elements act in different ways, it was also possible that these elements would not
be interchangeable in the µ gene context. Thus, to examine how the CoTC element will
affect the delicate balance between the competing poly(A) signal and splice reaction, we
placed the CoTC element in several locations within the Cµ4-M1 intron, in the presence
or absence of the µ pause element. It is known that changes in the length of the Cµ4M1 intron affect the pA/splice mRNA ratio, so expression of the constructs containing the
CoTC element were compared to constructs in which the Cµ4-M1 intron size was
modified with fragments not known to contain pause or CoTC activity. We find that the
CoTC located within the Cµ4-M1 intron near, but not far, from the µs poly(A) signal
affected µs/µm mRNA expression. In addition, we find no evidence for natural CoTC
activity in the µ gene.
RESULTS
The β globin CoTC at a distal position does not affect µ mRNA processing
To examine the how a CoTC element may effect µs/µm processing, we placed
the 800-bp β globin CoTC element at the KpnI site within the Cµ4-M1 intron (1200 bp
from the µs poly(A) and 500 nt upstream from the M1 3’ splice site), in the context of an
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intact µ gene, containing the Ig promoter and enhancer, a rearranged VDJ region, the
complete IgM constant region and about 2 kb of sequence downstream of the µm
poly(A) signal ((Peterson and Perry, 1989); Cµ/CoTC (+), Figure 4-1). Because the
CoTC and pause elements had similar effects on transcription termination in other
contexts (Gromak et al., 2006), we also inserted the CoTC into the µ gene from which
the pause had been deleted ∆NH/CoTC(+),
(
Fig ure 4-1).

We have shown previously

that the size of the Cµ4-M1 intron affects the µs/µm mRNA expression ratio; a shorter
intron decreases the pA/splice ratio while a longer intron increases it (Peterson, 1992;
Peterson, 1994b; Peterson et al., 1994; Peterson and Perry, 1986, 1989; Seipelt and
Peterson, 1995). Thus, to detect any effects specific to the CoTC rather than just
changes to the intron size, we made multiple intron size control constructs. In one, we
inserted the 800 bp CoTC into the Cµ4-M1 intron from which an 800 bp fragment had
been deleted (∆AR/CoTC(+), Fig ure 4-1), which places the CoTC element about 400 nt
downstream of the µs poly(A) signal. We also isolated CoTC element insertions in the
opposite, presumably inactive, orientation for these three constructs (CoTC(-) versions,
Figure 4-1). We also used other constructs containing various intron sizes described in
previous studies as controls (Table 2-1, Figure 4-1). These include∆NR, containing a
351 bp deletion between the NcoI and EcoRV sites; ∆AN, containing a 446 bp deletion
between the AccI and NcoI sites; ∆AR, containing a 797 bp deletion between the AccI
and EcoRV sites; ∆AR/pBR403 and ∆AR/rpI900 containing a 403 bp or 900 bp fragment
inserted at the KpnI site of ∆AR; and Cµ/rpI900, containing the 900 bp fragment inserted
at the KpnI site of Cµ (Peterson and Perry, 1986). All of these genes were stably
introduced into M12 B cells and S194 plasma cells, both of which do not express their
endogenous µ genes, and total RNA was analyzed by S1 nuclease mapping to measure
the relative expression of µs (pA) and µm (splice) mRNA (Figure 4-2). Since previous
placement of the CoTC into the β-globin intron did not affect expression, it was possible
that it would have no effect on µ gene expression. However, because this intron is
involved in the cis-competition with the µs poly(A) signal, it was possible that the CoTC
could affect the balance between these reactions; this cis-competition is sensitive so that
minor changes can be detected. Also, since this intron contains a pause element, we
could determine whether the CoTC element was able to replace this pause element as it
could in other genes.
Predictably, because inserting the CoTC element lengthened the Cµ4-M1 intron,
the pA/splice expression ratio increased for all CoTC(+) constructs relative to their
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starting constructs and this was observed in both B cells and plasma cells [Cµ vs.
Cµ/CoTC(+), ∆NH vs. ∆NH/CoTC(+) and ∆AR vs. ∆AR/CoTC(+), Figures 4-1 and 4-2].
The one exception was Cµ and Cµ/CoTC in plasma cells, which expressed similarly high
pA/splice mRNA ratios. To determine whether the CoTC element could replace the
pause element, we compared the Cµ and∆NH constructs to these genes that contain
the inserted CoTC element (Figures 4-1 and 4-2). In B cells, the pA/splice ratio of∆NH
is about 3-fold lower than Cµ. A similar difference in the pA/splice ratio is also seen
between Cµ/CoTC(+) and ∆NH/CoTC(+). This suggests the CoTC is not able to replace
the activity of the pause site when inserted at this location about 1 kb downstream from
where the pause site is normally located. It is interesting to note that various pause sites
inserted at this KpnI site also did not replace the activity lost by deletion of the NH pause
element (Peterson et al., 2002).
To better visualize the expression changes caused by the CoTC elements,
relative to the intron size controls, we plotted intron size vs the pA/splice expression ratio
(Figure 4-3). The ∆NH constructs, which lack the pause element have, by definition, an
effect that is greater than the size of the element and thus have not been included in this
plot. The trend of the greater intron size causing an increase in the pA/splice ratio can
clearly be seen from the size control constructs. While there is some scatter from a
straight line, which indicates that primary sequence or RNA structure also contributes to
the pA/splice ratio, the strong trend indicates that intron size is a major determinant of
the expression ratio. In general, the CoTC(+) constructs fall within the range expected
based on intron size, rather than having an increased pA/splice ratio that would indicate
a specific effect of the CoTC element. The constructs
∆AR/CoTC(+), ∆AR/rpI900 and
Cµ, which all have Cµ4-M1 introns of a similar size, all have similar expression ratios in
B cells (Figures 4-1 and 4-2), which is also consistent with the CoTC element not
affecting pA/splice ratio from the KpnI site location in the Cµ4-M1 intron.
Curiously, all the constructs with the CoTC element in the opposite orientation
had much lower expression ratios than expected based on the intron size (Figure 4-1,
Figure 4-2 and “x” in plots in Figure 4-3). It appears that the CoTC(-) fragment contains
activity that greatly enhances Cµ4-M1 splicing relative to cleavage-polyadenylation at
the µs poly(A) signal. Because expression is measured by S1 nuclease mapping, which
would not detect any aberrant splicing caused by this fragment, we performed multiple
RT-PCR reactions, as well as 3’ RACE, to determine whether the Cµ4 5’ splice site was
being spliced to a new 3’ splice junction. However, only the expected products were
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detected (data not shown). We propose that the enhanced splicing activity may be due
to a fortuitous splice enhancer sequence introduced with the anti-sense β-globin CoTC,
but we did not test this hypothesis further.
Because the expression data indicated that the CoTC element did not affect Ig
expression, we needed to determine whether this was because the CoTC element was
not being cleaved in the µ gene context. To do this, we performed semi-quantitative RTPCR using primers that flank the CoTC element using RNA extracted from M12 cells
expressing the constructs with the CoTC in both orientations (Figure 4-4, PCR 2).
Because the CoTC in the antisense orientation should not be cleaved, the RT-PCR
signal obtained for the CoTC(-) constructs will measure the amount of uncleaved intronic
RNA. If the CoTC element in the CoTC(+) constructs has been cleaved, an RT-PCR
product will not be amplified. Primers that amplify the region between the Cµ3 and Cµ4
exons were used to ensure similar expression levels among the constructs (Figure 4-4,
PCR 1). Because the signal across the CoTC insertion site was consistently higher in
the CoTC(-) constructs than the CoTC(+) constructs, we conclude that the CoTC
element is being cleaved in a major portion of the transcripts. However, because this
activity does not affect the pA/splice expression ratio, cleavage is likely occurring after a
commitment to one of the two competing reactions has been made.
The β-globin CoTC at a proximal position does affect µ mRNA processing
Because the CoTC element placed at the KpnI site in the Cµ4-M1 intron did not
affect µ alternative RNA processing choices and did not replace the activity of the NH
pause fragment, we determined whether this element could affect µ mRNA expression
from a location closer to the µs poly(A) signal. We cloned the CoTC element into the
HindIII site in the presence or absence of the NH pause element, so that the CoTC is
either 200 bp or 50 bp, respectively, downstream of the µs poly(A) signal (Cµ/CoTC-H
and ∆NH/CoTC-H, Figure 4-5A). This also places the CoTC element 1475 nt upstream
from the M1 3’ splice site.

As controls for intron size, we also inserted the rpI900

fragment into the same locations (Cµ/rpI900-H and ∆NH/rpI900-H, Figure 4-5A). RNA
from M12 cells stably expressing these constructs was analyzed by S1 nuclease
analysis (Figure 4-5B). Compared to Cµ and∆NH, the constructs containing the CoTC
element had dramatically increased pA/splice mRNA ratios. These ratios were about 3fold higher than the intron size controls, which indicates that the CoTC element is
affecting µ mRNA expression at this location. The pA/splice ratios for the constructs
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carrying the CoTC and rpI900 fragments in either the KpnI or HindIII sites are compared
in Figure 4-5D. It is interesting that the rpI900 fragment at either site leads to a similar
pA/splice ratio, indicating this ratio is mainly due to the intron size. However, while the
construct with the CoTC element at the KpnI site expresses a pA/splice ratio similar to
the constructs containing the rpI900 element, when the CoTC is placed in the HindIII
site, cleavage-polyadenylation at the µs poly(A) signal is greatly enhanced. Cµ/CoTC-H
and ∆NH/CoTC-H expressed similar pA/splice ratios, suggesting that the CoTC element
activity either replaced or dominated over the lost pause site activity in the ΔNH
construct. Thus, these experiments show that the CoTC, when placed close to the µs
poly(A) signal does affect the pA/splice ratio.
The CoTC element in the β globin gene is required for transcription termination
(Dye and Proudfoot, 2001), did not disrupt splicing of an 850 bp intron (Dye et al., 2006).
Thus, the high pA/splice expression ratio observed when the CoTC was located near the
µs poly(A) signal could be due to CoTC-induced early termination so that the complete
Cµ4-M1 intron wasn’t synthesized efficiently. It could do this either by enhancing use of
the µs poly(A) signal or by creating cleaved ends that are entry sites for 5’-3’
exonucleases. Alternatively, CoTC cleavage could interfere with Cµ4-M1 intron splicing;
this intron is about 1 kb longer than the β globin intron that was not affected.

To

examine the fate of RNA downstream of the CoTC element, we performed semiquantitative RT-PCR on total M12 RNA, using primers flanking the HindIII insertion site
and primers across the M1 3’ splice junction in both the CoTC-containing constructs and
the rpI900 size controls (PCR 2 and PCR 3, Figure 4-5C). As an expression control,
each sample was analyzed with primers in the Cµ3 and Cµ4 exons, which showed a
similar level of expression in all four constructs (PCR 1, Figure 4-5C). The RT-PCR
reaction across the CoTC or rpI900 fragment insertion site clearly showed a decrease in
RNA from the CoTC-containing constructs compared to the rpI900-containing
constructs; the product sizes vary due to the presence or absence of the NH pause
fragment and the difference in size between the CoTC and rpI900 fragments. This
difference in RNA abundance, seen with multiple dilutions of the RT reaction, suggests
that the CoTC element is being cleaved in a substantial population of transcripts. The
PCR reaction detecting RNA across the 3’ M1 splice junction shows an even greater
difference between the CoTC-containing constructs compared to the rpI900-containing
constructs.

A signal for the CoTC-containing constructs can be seen only with the

undiluted RT reaction, when the signal for the rpI900-containing constructs is over-
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amplified (left panel of Figure 4-5C). This lack of a downstream RNA signal suggests
that either the CoTC element is causing transcription to terminate before the M1 exons
or, if this RNA is transcribed, that it is rapidly degraded. Thus, while these results do not
distinguish between the possible mechanisms of CoTC actions, they are fully consistent
with previous results that demonstrated enhanced expression and termination due to the
CoTC (West and Proudfoot, 2009).

CoTC like-elements are not found in the µ gene
Transcription termination in the µ gene has been measured in both primary Blymphocytes and various lymphoid cell lines; in all cases, the transcription termination
region was further upstream in plasma cells or stimulated B cells than in B cell lines or
resting B cells.

It is not clear whether this change in termination pattern is due to

changes in the use of different poly(A) signals or whether termination sequences, such
as a CoTC element, that are more active in the plasma cells may be involved. Thus, we
examined the termination region of the µ gene for evidence of a CoTC element that may
contribute to termination, possibly in a developmental stage-dependent manner. CoTC
elements were identified previously using a nuclear run-on hybrid selection technique
that requires a high level of gene expression. The cleavage activity was confirmed by
RT-PCR reactions, using primers that spanned the predicted CoTC region (Dye and
Proudfoot, 2001; Yuan and Tucker, 1984); PCR products were produced when the RNA
was contiguous, but where the RNA had been cleaved, no PCR product was detected.
We used an RT-PCR approach to screen the µ gene sequences for CoTC activity
because expression levels are not sufficient for the hybrid selection technique. We
isolated nuclear RNA, to enrich for nascent RNA, from two lymphoid cell lines
expressing the endogenous µ gene, 38C-13, a B cell line and D2, a 38C-13-derived
hybridoma cell line (Nelson et al., 1983).

These two cell lines contain the same

productively rearranged µ gene allele expressed in different developmental stages to
produce different ratios of pA/splice µ mRNA.

These cell lines also have different

transcription termination profiles by nuclear run-on assays (Kelley and Perry, 1986). D2
terminates downstream of the µm poly(A) signal whereas 38C-13 transcription continues
over this region (Kelley and Perry, 1986). We designed sets of primers to amplify
overlapping regions of the µ gene spanning about 3.7 kb of sequence downstream of the
µs poly(A) signal (Figure 4-6A). As a positive control for RT-PCR amplification over the
sequences farther downstream from the µs poly(A) signal, we used an in vitro

80

transcribed RNA, containing about 600 nt upstream of the M1 exon and 1900-bp
downstream of the µm poly(A) site (denoted as the RV RNA, Figure 4-6A).

PCR

reaction “a” was used as the quantitation control to compare the signals between the
38C-13 and D2 RNAs and the amount of RNA used in the RT reactions was adjusted so
the signal intensity was similar. This adjusted amount of RNA (1 µg of 38C-13 and 2 µg
D2 RNA) was used in all the RT reactions. The primers a – e were used to make cDNA
from the two RNA samples. The cDNA was then amplified with the primers shown
(Figures 4-6A and 4-6B). If a CoTC existed within the µ gene, we would expect to see
an abrupt loss in PCR product from the RT primer that was downstream of the cleavage
site. If there were a CoTC element that was active selectively in one cell type, we would
only see this abrupt loss in one RNA sample. In fact, we observe a gradual decline in
PCR signal as we use primers further downstream from the µs poly(A) signal; the D2
signal declines relative to 38C-13 mostly over primers c and d (Figure 4-6C). This is in
good agreement with the nuclear run-on data that shows D2 termination downstream of
the µm poly(A) signal (Kelley and Perry, 1986). Thus, we find no evidence for a CoTC
element that contributes to transcription termination in the µ gene.
DISCUSSION
Transcription termination has been extensively studied in the IgM/IgD gene
(Peterson, 1994a). While B cells express both IgM and IgD and transcribe the entire
locus, transcription terminates between IgM and IgD in plasma cells so that IgD is no
longer expressed. However, termination is not required for the RNA processing shift
seen during B lymphocyte development because cells that express high pA/splice µ
mRNA ratios often terminate transcription downstream of the µm poly(A) signal. While
there are clear differences in the transcription termination regions in B cells compared to
plasma cells, little is known about the mechanism driving this, although changes in the
use of the µs poly(A) signal is a possible regulatory mechanism. Here, we explored
whether additional sequences such as CoTC elements, located within the Cµ4-M1 intron
or in sequences downstream of the µm poly(A) signal, are involved in transcription
termination in B cell and plasma cells. Using semi-quantitative RT-PCR and primers
spanning the region 3.7 kb downstream from the Cµ4 exon, we explored whether
nascent µ transcripts are cleaved co-transcriptionally. This event would result in an
abrupt loss of the PCR signal downstream of the cleavage site due to the loss of
continuity within the nascent RNA. However, this is not what we observed. Instead, we
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measured a gradual decrease in PCR signal across the region in both the B cell line
(38C-13) and the 38C-13-derived hybridoma cell line (D2). Termination was observed to
occur further upstream in the D2 cells, compared to 38C-13 cells, which is consistent
with run-on data from these cell lines (Kelley and Perry, 1986). Therefore, we conclude
that a CoTC element is not detectable in the µ gene. Thus, the most likely explanation
for transcription termination profile differences between B cells and plasma cells is that
changes in the µs poly(A) signal use drive differential termination (Peterson, 2007).
Because alternative RNA processing in the µ gene relies on a balanced
competition between a splice and a cleavage-polyadenylation reaction, subtle changes
that affect the efficiencies of either reaction can be sensitively detected in this gene. We
have shown that the µ gene contains an RNA pol II pause element between 50 and 200
nt downstream of the µs poly(A) signal that contributes to the efficient use of this poly(A)
signal in both B cells and plasma cells (Peterson et al., 2002).

To gain a better

understanding of the CoTC element from the β globin gene, and how it may function in
place of the µ pause site, we placed the 800 bp CoTC element within the Cµ4-M1 intron
at several different positions downstream of the µs poly(A) signal in the presence or
absence of the µ pause element. Because we knew that changes in the Cµ4-M1 intron
size would affect the pA/splice RNA ratio, we used a series of constructs containing
Cµ4-M1 introns of different lengths as controls for intron size. When the CoTC element
was inserted in the KpnI site in the active orientation (+), there was no effect on the
pA/splice mRNA ratio over and above that expected due to the intron length, whether the
pause site was present or not. In this set of constructs, the distance between the CoTC
element and the µs poly(A) signal varied from 400 nt∆AR/CoTC(+)
in
to 1200 nt in
Cµ/CoTC(+), but the distance between the CoTC element and the M1 3’ splice junction
was a constant 500 nt. In contrast, when the CoTC element was placed in the HindIII
site, use of the µs poly(A) signal was greatly enhanced.

In these constructs, the

distance between the CoTC element and the µs poly(A) signal was either 200 nt in
Cµ/CoTC-H or 50 nt in∆NH/CoTC -H whereas the distance between the CoTC and the
M1 3’ splice junction is 1475 nt. We showed that, in both locations, the CoTC element
was causing RNA cleavage, as seen by a decrease in RT-PCR signal across the
cleavage element compared to a similarly placed fragment without cleavage activity.
Thus, the difference between the CoTC affecting µ processing from one intronic location
but not another must be due to its position within the intron rather than differences in the
fragment activity. There are several possible explanations for this position effect, based
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on whether the spacing between the µs poly(A) signal and CoTC or the spacing between
the CoTC and the M1 3’ splice junction is more critical.
Previous studies in our lab showed that the µ pause region increased usage of
the µs poly(A) site when it was positioned up to 100 bp downstream of its normal
location.

However, if the pause element was moved further away, effects on the

pA/splice RNA expression were lost (Burnside et al., 2011). It is possible that we are
detecting a similar strict distance effect with the CoTC at 200 nt from the µs poly(A)
signal being able to affect the pA/splice RNA expression whereas all effects are lost at a
position 400 nt from the µs poly(A) signal. The basis for the limited spacing between the
µs poly(A) signal and pause elements is not yet clear, but it suggests that a poly(A)
signal is able to respond to pausing over a limited distance or a limited time after being
synthesized. Although it hasn’t been systematically examined, other studies that have
measured the effects of pause sites and CoTC elements on transcription termination
have not described a distance effect. Indeed, the β globin CoTC is naturally located 800
nt from the β globin poly(A) signal although it continued to direct transcription termination
when it was relocated to 200 nt from the poly(A) signal (Dye and Proudfoot, 2001). A
major difference between these assays is that in the µ gene we measure affects on
alternative RNA processing choices of the nascent RNA, not just transcription
termination.
While it is possible that the poly(A) signal – CoTC spacing affects whether the
CoTC impacts µ RNA processing, perhaps a more likely interpretation is that the
distance between the CoTC and the M1 3’ splice site is the more important variable that
determines whether the CoTC affects µ mRNA processing or not. We have previously
explained the effect of intron size on the pA/splice RNA ratio in terms of the relative
timing between when the µs poly(A) signal and the complete competing intron are
synthesized; a smaller intron would allow less time for the µs poly(A) signal to be
recognized before the splice reaction could begin to compete. This same relative timing
explanation may be used to interpret the position effect of the CoTC element. In the
constructs in which the CoTC does affect the pA/splice RNA ratio, this distance is 1475
nt, whereas it is 500 nt in the constructs in which the CoTC has no effect. Thus, with
only 500 nt to be synthesized, the complete intron will be present in the nascent
transcript sooner, so the CoTC cleavage reaction likely occurs after the nascent RNA is
committed to one of the two competing reactions. However, significant cleavage of the
CoTC may occur before the M1 3’ splice junction is synthesized when this distance is
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1475 nt and this cleavage may drive transcription termination. Indeed, we have shown
that there was a dramatic decrease in nascent RNA over the M1 exon in constructs
containing the CoTC element in this location, consistent with the idea that CoTC
cleavage is causing transcription termination so that the complete Cµ4-M1 intron was
not synthesized efficiently to compete with the µs poly(A) signal. This interpretation,
based on timing, also is consistent with previous studies that introduced the β globin
CoTC, a hammerhead ribozyme or the hepatitis δ ribozyme within the introns of the β
globin gene. The fast-cleaving hepatitis δ ribozyme, but not the CoTC or hammerhead
ribozyme affected expression of β globin mRNA (Dye et al., 2006; Fong et al., 2009).
This suggested that RNA processing was disrupted by the faster cutting hepatitis δ
ribozyme, which did not allow time for co-transcriptional spliceosome assembly before
the nascent RNA was cleaved.

However, the slower cleaving CoTC element and

hammerhead ribozyme did allow the spliceosome to commit the pre-mRNA to be spliced
before the intron was cleaved and thus did not affect overall mRNA expression. The
lengths of the β globin introns are 130 and 850 nt, so the distances between the CoTC
and the splice junctions are, in general smaller than in the µ gene. It is possible that a
systematic study of the distances over which effects can be detected could be used to
estimate how rapidly these various RNA cleavage activities occur in vivo, relative to
transcription elongation which has been measured to be about 3.8 kb min-1 (Singh and
Padgett, 2009).
Previous studies on transcription termination have shown that pol II pause sites
and CoTC elements are interchangeable to facilitate termination downstream from
functional poly(A) signals (Gromak et al., 2006; West and Proudfoot, 2009; West et al.,
2008).

When we placed the CoTC element in the HindIII site of the Cµ4-M1 intron,

directly downstream of the µs poly(A) signal in either the presence or absence of the µ
pause site region, we saw a dramatic increase in the pA/splice RNA ratio, from 2.4 in the
wild-type gene to 23-24, but we no longer detected an expression difference due to the
pause site. This suggests that the CoTC element activity dominates in this location.
When other pause sites were substituted for the µ pause element, several were shown
to be stronger because they caused an increase the pA/splice ratio compared to the
wild-type gene, from 2.4 to 6-8 (Burnside et al., 2011).

Interestingly, transcription

terminated further upstream in the µ genes with the stronger pause sites. Thus, it seems
that the pause and CoTC elements may be interchangeable for directing transcription
termination in this µ gene context; cleavage at the CoTC element drove early termination
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and thus a high pA/splice ratio whereas strong pause sites increased use of the µs
poly(A) signal which then drove early termination.

An increase in the pA/splice

expression ratio was seen in each case. We did not determine whether the constructs
containing the CoTC at the HindIII site were regulated between B cells and plasma cells.
Since the pA/splice was already very extreme in B cells, we would have been able to
measure only a 2-3-fold increase in plasma cells before we reached the limits of our
assay. Thus, the regulatory mechanism is likely to have been blunted due to the strong
effect of the CoTC element.
While it is important to study transcription termination in simple transcription units
to establish the connections between poly(A) signals and downstream termination
elements, it is also valuable to consider these events in a more complex transcription
units such as the µ gene where poly(A) site use, pause sites and transcription
termination are developmentally regulated to alter RNA processing reactions. A major
conclusion from studying termination in β globin constructs was that poly(A) signal
recognition, not cleavage, is sufficient for termination in the presence of a terminator
such as the CoTC element (West and Proudfoot, 2008). However, simply having a
poly(A) signal appear in the nascent transcript can not be sufficient for termination in the
µ gene because the µs poly(A) signal, the first of two poly(A) signals, is not recognized
efficiently in B cells and transcription does not terminate until after the downstream µm
poly(A) signal is used. In plasma cells, use of the first µs poly(A) signal predominates
and termination occurs sooner than in B cells. Thus, there must be a mechanism to
regulate when a poly(A) signal is recognized to trigger termination or to make the pol II
“termination prone” and when it is skipped so transcription continues. Because the µ
transcription unit is both complex in structure and is regulated during B lymphocyte
development, it is a unique model system to understand how the basic steps of
transcription termination can be modulated to lead to different gene expression
outcomes.
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Figure 4-1. The CoTC element inserted in the Cµ4-M1 intron at the KpnI site does
not affect the pA/splice mRNA expression ratio besides that expected due to
changes in intron size. The map of the µ gene 3’ region containing the competing µs
poly(A) signal (µs pA) and the Cµ4-M1 splice (dotted line) is shown at the top. The Cµ4
exon common to both µs and µm mRNA is shown as a black box, the µs-specific exon is
shown as a white box and the µm-specific exons M1 and M2 are shown as grey boxes.
The previously described pol II pause site region is denoted by the small light grey box.
Restriction sites used in cloning are shown: N, NotI; H, HindIII;, A, AccI; N, NcoI; RV,
EcoRV; K, KpnI. Listed below the map are the CoTC insertion constructs and the intron
size controls (in italics), the size of each Cµ4-M1 intron, a diagram of the intron structure
with a bar denoting deleted sequence and a triangle denoting an inserted fragment and
the pA/splice expression ratio for each construct in M12 B cells and S194 plasma cells.
Expression was measured by S1 nuclease analysis from cell lines stably transfected
with each construct (see Figure 4-2); the average and standard deviation of at least
three analyses are shown.
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Figure 4-2. S1 nuclease analysis of the CoTC constructs and controls. (A) Diagram
of the end-labelled probe used to distinguish mRNA spliced at the Cµ4 5’ splice junction
from mRNA that is cleaved and polyadenylated at the µs poly(A) signal. (B)
Representative S1 analyses for the constructs shown above the lanes stably expressed
in M12 B cells; the bands for probe, mRNA that is cleaved and polyadenylated at the µs
poly(A) signal (pA) and mRNA spliced at the Cµ4 5’ splice junction (splice) are denoted
on the right. (C) Representative S1 analyses for the constructs shown above the lanes
stably expressed in S194 plasma cells; the bands for probe, mRNA that is cleaved and
polyadenylated at the µs poly(A) signal (pA) and mRNA spliced at the Cµ4 5’ splice
junction (splice) are denoted on the right.
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Figure 4-3. The pA/splice expression ratio increases with increasing intron size.
The pA/splice expression ratios, in both B cells (top panel) and plasma cells (lower
panel), for the CoTC(+) and CoTC(-) constructs and intron size control constructs are
plotted versus the intron size. The data are taken from Figure 4-1.
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Figure 4-4. The CoTC element inserted at the KpnI site is being cotranscriptionally cleaved. (A) Map of the µ gene 3’ region, as in Figure 4-1, showing
the locations of the two sets of PCR primers used to analyze RNA from cells stably
expressing µ genes containing the CoTC element. PCR 1 (primers Cµ3T and C4B,
Tabla 2-2) spans exons Cµ3 and Cµ4 and will detect all spliced µ mRNA. PCR 2 (Kpn-T
and Kpn-B, Table 2-2) spans the KpnI site that contains the CoTC(+) and CoTC(-)
elements. (B) RT-PCR reactions using RNA from M12 B cells stably expressing the
constructs shown above each lane. The sizes of the marker lanes (M) and the size of
the PCR products are shown. RT reactions in which the reverse transcriptase enzyme
was omitted were used in the PCR reactions to ensure there was no DNA contamination
in the RNA samples; all reactions were blank (data not shown).
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Figure 4-5. The CoTC element inserted at the HindIII site affects expression of the
µ gene. (A) Map of the µ gene 3’ region, as in Figure 4-1, showing the locations of the
three sets of PCR primers used to analyze RNA from cells stably expressing µ genes
containing the CoTC element or the rpI900 size control fragment. The site of fragment
insertion is shown. PCR 1 (primers Cµ3T and C4B, Table 2-2) spans exons Cµ3 and
Cµ4 and will detect all spliced µ mRNA. PCR 2 (Apa and Hind, Table 2-2) spans the
region that contains the CoTC and rpI900 fragments. PCR 3 (Kpn-T and M1B, Table 22) spans the M1 3’ splice junction. (B) Representative S1 analyses for the constructs
shown above the lanes stably expressed in M12 B cells; the bands for probe, mRNA that
is cleaved and polyadenylated at the µs poly(A) signal (pA) and mRNA spliced at the
Cµ4 5’ splice junction (splice) are denoted on the right. The average and standard
deviation of at least three independent analyses are shown below each lane. This figure
was assembled from multiple gels. (C) RT-PCR reactions using RNA from M12 B cells
stably expressing the constructs shown above each lane. The sizes of the marker lanes
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(M) and the size of the PCR products are shown. The panel on the left used the
undiluted RT reaction in the PCR. The RT reactions were diluted 1:3 for the PCR
reactions in the right panel. The PCR 2 products vary in size because of differences in
the size of the CoTC and rpI900 fragments and because of the presence or absence (in
∆NH) of the NH pause region. (D) Graph of the pA/splice expression ratio for the
constructs shown along the bottom, with the CoTC element or rpI900 fragment in either
the KpnI site (black bars) or the HindIII site (white bars). The control Cµ and ΔNH
constructs are shown for comparison (grey bars).
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Figure 4-6. There is no evidence for a natural CoTC element in the µ gene. (A) Map
of the µ gene 3’ region, as in Figure 4-1, but extending downstream to the EcoRV site,
about 400 nt upstream of the first IgD exon. (Cδ1, cross-hatched box). Below in the
hatched slim box is shown the region in vitro transcribed as the RV RNA used as a
positive control. Below the map is the scheme used to explore the µ gene for CoTC
elements: the arrows marked “a” – e” are the RT primers used to make cDNA (denoted
by dashed line) from the 38C-13 B cell line and D2 hyridoma cell line nuclear RNAs and
the arrows connected by a solid line are the primers to make the PCR products from
each RT reaction. The sizes of the PCR products are indicated on the left. (B) RT-PCR
reactions from nuclear RNA from the 38C-13 (38C) B cell line or its hybridoma partner
D2 or the in vitro transcribed RNA RV. The RT primers used are shown on the left and
correspond to the map in A and the PCR product sizes are shown on the right. One µg
of 38C-13 RNA and 2 µg of D2 RNA were used in each RT reaction to generate similar
product intensity in RT-PCR “a”. The primers used are (Table 2-2): “a”, 432AS for RT
and CµpA-T and 432AS for PCR; “b”, 1528AS for RT and CµpA-T and 432AS for PCR;
“c”, M2-B for RT and Kpn-T and M2-B for PCR; “d”, 469-T for RT and M2-T and 469-T
for PCR; “e”, 473AS for RT and 469-T and 473AS for PCR. (C) The ratio of the D2 to
38C PCR signals for each RT-PCR reaction were quantitated from two to four
independent RT-PCR reactions and graphed.

Copyright  Lilia M. Turcios 2011
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CHAPTER V
CONCLUSIONS AND STATEMENT OF SIGNIFICANCE
Regulation of gene expression occurs at multiple levels and it is now recognized
that modulation of RNA processing during transcription contributes to the complexity of
how and when a gene may be expressed. Many human diseases have been attributed
to misregulation of gene expression where RNA processing steps such as splicing, are
involved. Therefore, a better understanding of the mechanisms by which transcription is
coupled to RNA processing could be used to develop therapeutic tools to improve
human health. Here, I studied two different model genes: the AFP and the µ genes to
investigate different post-transcriptional events where a change in RNA processing is
responsible for developmental changes in gene expression.
Early studies identified that AFP developmental repression by Zhx2 not only
requires the AFP promoter (Peyton et al., 2000a) but it also involves post-transcriptional
events (Morford, Unpublished; Vacher et al., 1992). These data suggested that Zhx2
may control accumulation of AFP mRNA levels by a mechanism that couples
transcription and posttranscriptional events (Figure 1-1) (Peyton et al., 2000a). In this
work, we described one of the post-transcriptional steps involved in AFP developmental
repression by Zhx2. We observed that splicing efficiency of AFP transcripts is greatly
reduced in the presence of Zhx2. The global repression of AFP pre-mRNA splicing may
explain the reduced levels of AFP expression in adult mouse liver, when Zhx2 levels are
higher than in pre-natal stage. Moreover, inhibition of AFP pre-mRNA splicing may also
explain the presence of the unprocessed AFP RNA in the cytoplasm, maybe due to an
increase in AFP pre-mRNA stability. It is possible that the extraordinary stability of AFP
transcripts may be attributed to the absence of exon junction complex (EJC) complexes
that are normally deposited during splicing. This in turn would avoid recruitment of NMD
core effectors, allowing the unprocessed AFP transcripts escape from this surveillance
mechanism.
One hypothesis about the mechanism of AFP repression by Zhx2 is that Zhx2
may interfere with recruitment of some factors required for coupling transcription with
RNA processing.

Because the promoter is required for AFP regulation by Zhx2,

recruitment of these factors may occur in a promoter dependent-manner during preinitiation complex formation, transcription initiation and/or early transcription elongation
(Figure 1-1, steps 1 through 3).

There are only a few reported examples where
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uncoupling of transcription with RNA processing leads to full length unprocessed RNA.
Two of these examples are the TNF gene in naïve T cells and the primary response
genes (PRGs) in unstimulated macrophages (described in discussion of chapter III). In
the case of naïve T cells, TNF pre-mRNA splicing is blocked.

Soon after T cell

activation, the accumulated TNF pre-mRNA is properly spliced, allowing immediate TNF
protein expression.

The mechanism by which TNF pre-mRNA splicing is co-

transcriptionally repressed and then post-transcriptionally activated is not yet known. In
the case of unstimulated macrophages, the promoters of the PRGs are pre-associated
with S5-phosphorylated RNAPII before LPS stimulation, allowing production of full-length
pre-mRNA that is quickly degraded. Upon LPS stimulation, p-TEFb is recruited, through
Brd4, to phosphorylate RNAPII at S2, which results in the generation of mature RNA and
expression of PRGs. These examples clearly indicate that regulation of RNA processing
can affect gene expression as a mechanism that allows quick response to stimuli. In
addition to p-TEFb, the Spt5 subunit of DSIF is known to be recruited during
transcription initiation and accompanies the RNAPII during transcription elongation
(Sims et al., 2004b). The Spt5 subunit has been shown to participate in different RNAPII
protein complexes and to interact with RNA processing factors such as capping
enzymes (Lindstrom et al., 2003; Sims et al., 2004b). Moreover, mutations in Spt5
cause splicing defects in yeast, indicating it is required for coupling transcription and
mRNA maturation (Lindstrom et al., 2003). Based on all these data, factors involved in
regulation of RNAPII CTD phosphorylation and recruitment of RNA processing factors,
such as P-TEFb and Spt5, may be potential candidates to participate in Zhx2 regulation.
To investigate whether the presence of Zhx2 alters the phosphorylation pattern of
RNAPII CTD across the AFP gene, ChIP assays could be performed using antibodies
that specifically recognize either S5- or S2-phosphorylated forms of the RNAPII CTD.
We may expect a reduction in S2- CTD phosphorylation toward the end of the AFP gene
if Zhx2 interferes with this process. Recruitment of factors such as pTEF-b and Spt5
also could be determined by ChIP assays. Additionally, identification of Zhx2-interacting
proteins by proteomic analysis should provide significant clues to the post-transcriptional
steps involved in Zhx2 regulation.

Investigation of the AFP splicing repression

mechanism by Zhx2 may increase our understanding of how gene expression could be
regulated at early transcription steps (Figure 1-1, steps 1 through 3). This knowledge
may be extended to other gene systems and used as tool for amelioration of human
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diseases. This information also can be used to optimize cell culture systems so that
they will reproduce the AFP similar repression levels observed in the mouse model.
In addition to AFP regulation, Zhx2 seems to have an important role in regulating
expression of other genes, such as those involved in lipid metabolism. For instance,
BALB/cJ mice, which express low levels of Zhx2, have reduced triglyceride levels
compared to BALB/cJ mice expressing a Zhx2 transgene in the liver, when fed with a fat
diet (Gargalovic et al., 2010).

It was determined that reduced triglyceride levels in

BALB/cJ mice are, in part, due to the enhanced lipoprotein lipase (Lpl)-mediated lipolysis
and plasma clearance of triglyceride-rich plasma lipoproteins. Since Zhx2 negatively
impacts expression of genes involved in lipid metabolism such as Lpl, low expression of
Zhx2 may have a protective effect on atherosclerosis and heart diseases (Gargalovic et
al., 2010). Additionally, the role of Zhx2 in cancer is not well established because RNA
expression data and protein array are not consistent to each other (Hu et al., 2007; Lv et
al., 2006). It is possible, that subcellular localization of Zhx2 is perturbed in disease
states. If that were the case, studies on Zhx2 post-translational modifications may be
performed and contribute to the overall understanding of the Zhx2 regulatory
mechanism.
In contrast to the AFP gene, where regulation of gene expression occurs at an
early step before pre-mRNA enters the splicing pathway, the µ gene developmental
expression is due to regulated changes in cleavage/polyadenylation and splicing that
ultimately affects transcription termination (Figure 1-1, steps 3 and 4 and Figure 1-5).
Because CoTC elements are known to drive transcription termination in some genes
such as the human β-globin, the human ε-globin and the mouse albumin genes, we
decided to study whether the CoTC elements may drive transcription termination
differences in the µ gene that occur during B cell differentiation to plasma cell. We did
not find evidence of a CoTC element in the Cµ4-M1 intron or further downstream of the
M2 exon. Therefore, we utilized the complex gene structure of the µ gene to better
understanding the effect of cleaving the pre-mRNA within the Cµ4-M1 intron on the µ
gene RNA processing. We did show that a cleavage induced by the β-globin CoTC
element can affect the pA/splice mRNA ratio in certain intronic positions. Inserting the βglobin CoTC within the Cµ4-M1 intron induced cleavage of the RNA transcript
independent of where it was located, but only insertion of the CoTC element
downstream of the µspA dramatically affected the balance of the two competing
reactions to enhance usage of the µspA. We explain this positional effect based on
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timing (Figure 5-1). The presence of the CoTC toward the end of the Cµ4-M1 intron
(KpnI site) may allow enough time for proper co-transcriptional spliceosome assembly
before cleavage occurs and thus splicing could compete with cleavage/polyadenylation
at µspA (Figure 5-1A).

However, when the CoTC element is present directly

downstream of the µspA, cleavage may occur before spliceosome assembly so that
splicing can not outcompete cleavage/polyadenylation at µspA (Figure 5-1B).

In

addition, the CoTC element drives early transcription termination. Several studies have
addressed the effect on splicing by inducing cleavage within an intron (Dye et al., 2006;
Fong et al., 2009). It was observed that a fast-cutting ribozyme such as the δ ribozyme
impairs splicing, while insertion of a slower-cutting ribozyme or the β-globin CoTC
element did not have the same effect. It was concluded that splicing is affected when
cleavage within the intron is fast enough to interfere with the co-transcriptional
spliceosome assembly (Fong et al., 2009). Here, we extended these findings using the
µ gene where a splicing reaction is in competition with a cleavage/polyadenylation
reaction.

We observed that indeed, the CoTC element could affect splicing when

inserted close to the 5’ splice site and in this case, it enhances the cleavage at the µspA
which results in higher µs mRNA production, rather than leads to an unproductive
transcript.

These results can also support evidence about microRNA (miRNA)

processing. MiRNAs are noncoding RNA species of ∼22 nt that are involved in post-

transcriptional gene silencing (Kim and Kim, 2007). These RNAs are encoded not only
within intergenic regions but also within introns of protein-coding transcrips. MiRNA

processing includes cleavage by Drosha to release ∼70 nt pre-miRNAs that are then

processed by Dicer to generate mature ∼22 nt miRNAs. This raises the question of how

intronic miRNA are processed without disrupting proper RNA processing of mRNAs (Kim
and Kim, 2007). Our studies together with those mentioned above support the idea that

Drosha may excise intronic miRNA after splicing is committed (Fong et al., 2009; Kim
and Kim, 2007).
Better understanding of µ gene RNA processing regulation could improve our
knowledge of the cis- and trans-acting factors involved in alternative RNA processing
and the mechanism involved in that regulation. The µ gene with its complex gene
structure can serve as a model for studying splicing, cleavage/polyadenylation and
transcription termination. The information gained about the µ gene regulatory
mechanisms could be extended to other gene systems to modulate gene expression
under pathological conditions.

96

Figure 5-1. Model of the β-globin CoTC element insertion effect on µ gene RNA
processing. (A) Insertion of CoTC element at the KpnI site with in the Cµ4-M1 intron.
(B) Insertion of CoTC element at the HindIII site with in the Cµ4-M1 intron.

Copyright  Lilia M. Turcios 2011
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